CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 75-796

APPROVED DRAFT LABELING

Cyclic Tablet Dispensers 1 28 Tablets 28 PREGIMEN

6 Cyclic Tablet Dispensers x 28 Tablets 28 PAY REGIMEN

Aviane™ (levonorgestrel and ethinyl estradiol tablets)

IR only

B only

Aviane™ (levonorgestrel and

ethinyl estradiol tablets)

Storage: Store at 25°C ($77^\circ F$): excursions permuted to 15°-30°C (59°-86°F). (See USP controlled room temperature)


DURAMED PHARMACEUTICALS, INC. CINCINNATI, OHIO 45213 USA


NDC 51285-017-28



Date:


Item: Aviane™—28 Carton Levonorgestrel/EE 0.10mg/0.02mg Part#: C00605 ISS. 09/00 Software: ILLUSTRATOR . 8.0 **COLORS** Approval Signatures Date THIS PROOF IS: OK as is; proceed with order OK to proceed with corrections Corrections; submit new proof





Day 2" x 2.494" 09/00 08 . 8.0	APR 30 2001	Date order v proof
Aviane TM 28 Card — 3.87 C00604 ISS.	288 BLU 327 0	Approval Signatures Date THIS PROOF IS: OK as is; proceed with order OK to proceed with corrections Corrections; submit new proof
Item: Part#: Software:		Approv

Usual Dosage: One tablet daily for 21 consecutive days per menstrual Cycle according to prescribed schedule. See enclosed information. Storage: Store at 25°C (77°F): excursions permitted to 15°-30°C (59°-86°F). (See USP controlled room temperature) After removing the aluminum-foil over wrap, avoid humd conditions and Protect from light by storing the dispenser card in the opaque vinyl folder provided. Read both sides.	Avione Avione (levonorgestrel and ethinyl estradiol tablets) 21 DAY REGIMEN Contents: One cyclic tablet dispenser of 21 tablets Each tablet contains 0.10 mg levonorgestrel with 0.02 mg ethinyl estradiol. By only This product (Like all oral contraceptives) is intended to prevent pregnancy. It does not protect against hiv infection (AIDS) and other sexually transmitted diseases.		Seal Line
Seal Line	· · · · · · · · · · · · · · · · · · ·	Seal Line	Seal Line





Item:

Aviane™ 21 Day Card — 3.872" X 2.494"

Part#:

C00603 ISS. 09/00

Software: ILLUSTRATOR . 8.0

COLORS

288 BLU







514 PNK

Approval Signatures	Date _		

THIS PROOF IS:


	OK as	is:	proceed	with	orde
!	Un as	15,	proceed	VVIU I	UIUE

OK to proceed with corrections

Corrections; submit new proof

	SUN	MON	TUE	WED	THU	FRI	SAT	
Start								•
•							:	į
Veek 2							1	ļ
•								(See OS
Veek 3							:	contro
•				Z :				700
				APR 30	ان ان			n (empe
				٠ 0	8			eurne)
Δ	vian	e denom	· netnal and athin	yl estralija ble		21 Day	l	

Usual Dosage: One orange tablet daily for 21 consecutive days followed by one light-green inert tablet for seven consecutive days, according to prescribed schedule. See enclosed information. Storage: Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). (See USP controlled room temperature) After removing the aluminum-foil overwrap, avoid humid conditions and protect from light by storing the dispenser card in the opaque vinyl folder provided. Read both sides.	Aviane Aviane (levonorgestrel and ethinyl estradiol tablets) 28 DAY REGIMEN Contents: One cyclic tablet dispenser of 28 tablets Twenty-one orange tablets, each containing 0.10 mg levonorgestrel with 0.02 mg ethinyl estradiol and seven light-green inert tablets. By only This product (Like all oral contraceptives) is intended to prevent pregnancy. It does not protect against hiv infection (Aids) and other sexually transmitted diseases.	DURAMED PHARMACEUTICALS, INC. CINCINNATI, OHIO 45213 USA C00606	Seal Line
Seal Line	Fold Line	Seal Line	Seal Line



Aviane" - 21 & 28

(levonorgestrel and ethinyl estradiol tablets)

DETAILED PATIENT LABELING

This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV intection (AIDS) and other sexually transmitted diseases.

DURAMED PHARMACEUTICALS, INC. CINCINNATI, OHIO 45213 USA

100397

ISS. 09/00

4

APPROVED

APR 30 2001

INTRODUCTION

Any woman who considers using oral contraceptives (the birth-control pill or the pill) should understand the benefits and risks of using this form of birth control. This leaflet will give you much of the information you will need to make this decision and will also help you determine if you are at risk of developing any of the serious side effects of the pill. It will tell you how to use the pill properly so that it will be as effective as possible. However, this leaflet is not a replacement for a careful discussion between you and your health-care provider. You should discuss the information provided in this leaflet with him or her, both when you first start taking the pill and during your revisits. You should also follow your health-care provider's advice with regard to regular check-ups while you are on the pill.

EFFECTIVENESS OF ORAL CONTRACEPTIVES

Oral contraceptives or 'birth-control pills' or 'the pill' are used to prevent pregnancy and are more effective than other nonsurgical methods of birth control. When they are taken correctly, the chance of becoming pregnant is less than 1.0% per year when used perfectly, without missing any pills Typical failure rates are less than 3.0% per year. The chance of becoming pregnant increases with each missed pill during the menstrual cycle. In comparison, typical failure rates for other methods of birth control during the first year of use are as follows:

IUD: 3%

Depo-Provera® (injectable progestogen): 0.3%

Norplant® System (implants): 0.1% Diaphragm with spermicides: 18%

Spermicides alone: 21%

Male condom alone: 12%

Female condom alone: 21%

Cervical cap

Nullinarous women: 18%

Parous women: 36%

Periodic abstinence: 20% No methods: 85%

WHO SHOULD NOT TAKE ORAL CONTRACEPTIVES

Cigarette smoking increases the risk of serious adverse effects on the heart and blood vessels from oral-contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should not smoke.

Some women should not use the pill. For example, you should not take the pill if you are pregnant or think you may be pregnant. You should also not use the pill if you have had any of the following conditions:

- · Heart attack or stroke
- Blood clots in the legs (thrombophlebitis), lungs (pulmonary embolism). or eyes.
- · Blood clots in the deep veins of your legs.
- · Known or suspected breast cancer or cancer of the lining of the uterus, cervix or vagina.
- Liver tumor (benign or cancerous).

Or, if you have any of the following:

- Chest pain (angina pectoris).
- Unexplained vaginal bleeding (until a diagnosis is reached by your doctor).
 Yellowing of the whites of the eyes or of the skin (jaundice) during pregnancy or during previous use of the pill.
- Known or suspected pregnancy.

Tell your health-care provider if you have ever had any of these conditions. Your health-care provider can recommend another method of birth control. OTHER CONSIDERATIONS BEFORE TAKING ORAL CONTRACEPTIVES

Tell your health-care provider if you or any family member has ever had:

- · Breast nodules, fibrocystic disease of the breast, an abnormal breast X-ray or mammogram.
- Diabetes.
- Elevated cholesterol or triglycerides.
- High blood pressure.
- · Migraine or other headaches or epilepsy. Mental denression
- · Gallbladder, heart or kidney disease.

· History of scanty or irregular menstrual periods.

Women with any of these conditions should be checked often by their health-care provider if they choose to use oral contraceptives. Also, be sure to inform your doctor or health-care provider if you smoke or are on any medications

RISKS OF TAKING ORAL CONTRACEPTIVES

1. Risk of developing blood clots

Blood clots and blockage of blood vessels are the most serious side effects of taking oral contraceptives and can be fatal. In particular, a clot in the legs can cause thrombophlebitis and a clot that travels to the lungs can cause a sudden blocking of the vessel carrying blood to the lungs. Rarely, clots occur in the blood vessels of the eye and may cause blindness, double vision, or impaired vision. If you take oral contraceptives and

need elective surgery, need to stay in bed for a prolonged illness, or have recently delivered a baby, you may be at risk of developing blood clots. You should consult your doctor about stopping oral contraceptives three to four weeks before surgery and not taking oral contraceptives for two weeks after surgery or during bed rest. You should also not take oral contraceptives soon after delivery of a baby or a midtrimester pregnancy termination. It is advisable to wait for at least four weeks after delivery if you are not breast-feeding. If you are breast-feeding, you should wait until you have weaned your child before using the pill. (See also the section on breast-feeding in "GENERAL PRECAUTIONS.")

2. Heart attacks and strokes

Oral contraceptives may increase the tendency to develop strokes (stoppage or rupture of blood vessels in the brain) and angina pectoris and heart attacks (blockage of blood vessels in the heart). Any of these conditions can cause death or serious disability.

Smoking greatly increases the possibility of suffering heart attacks and strokes. Furthermore, smoking and the use of oral contraceptives greatly increase the chances of developing and dying of heart disease.

3. Gallbladder disease

Oral-contraceptive users probably have a greater risk than nonusers of having gallbladder disease, although this risk may be related to pills containing high doses of estrogens.

In rare cases, oral contraceptives can cause benign but dangerous liver tumors. These benign liver tumors can rupture and cause tatal internal bleeding. In addition, a possible but not definite association has been found with the pill and liver cancers in two studies in which a few women who developed these very rare cancers were found to have used oral contraceptives for long periods. However, liver cancers are extremely rare. The chance of developing fiver cancer from using the pill is thus even rarer.

5. Cancer of the reproductive organs

There is, at present, no confirmed evidence that oral contraceptives increase the risk of cancer of the reproductive organs in human studies. Several studies have found no overall increase in the risk of developing breast cancer. However, women who use oral contraceptives and have a strong family history of breast cancer or who have breast nodules or abnormal mammograms should be closely followed by their doctors.

Some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. However, this finding may be related to factors other than the use of oral contraceptives

ESTIMATED RISK OF DEATH FROM A BIRTH-CONTROL METHOD OR PREGNANCY All methods of birth control and pregnancy are associated with a risk of developing certain diseases which may lead to disability or death. An estimate of the number of deaths associated with different methods of birth control and pregnancy has been calculated and is shown in the following table

ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN, BY FERTILITY-CONTROL METHOD AND ACCORDING TO AGE Method of control and outcome 15-19 20-24 25-29 30-34 No fertility-control methods 7.0 74 91 148 25.7 28.2 Oral contraceptives nonsmoker** 0.3 0.5 0.9 13.8 31.6 Oral contraceptives 117.2 smoker* 2.2 6.6 13.5 51.1 ייםטי 0.8 8.0 1.0 1.0 Condom' 16 0.7 0.2 0.3 0.4 Diaphragm/spermicide* 1.9 1.2 1.2 1.3 2.2 2.8 Periodic abstinence* 3.6

In the above table, the risk of death from any birth-control method is less than the risk of childbirth, except for oral-contraceptive users over the age of 35 who smoke and pill users over the age of 40 even if they do not smoke. It can be seen in the table that for women aged 15 to 39, the risk of death was highest with pregnancy (7 to 26 deaths per 100,000 women, depending on age). Among pill users who do not smoke, the risk of death was always lower than that associated with pregnancy for any age group except for those women over the age of 40, when the risk increases to 32 deaths per 100,000 women, compared to 28 associated with pregnancy at that age. However, for pill users who smoke and are over the age of 35 the estimated number of deaths exceeds those for other methods of birth control. If a woman is over the age of 40 and smokes, her estimated risk of death is four times higher (117/100,000 women) than the estimated risk associated with pregnancy (28/100,000 women) in that age group.

The suggestion that women over 40 who don't smoke should not take oral contraceptives is based on information from older high-dose pills and on less-selective use of pills than is practiced today. An Advisory Committee of the FDA discussed this issue in 1989 and recommended that the benefits of oral-contraceptive use by healthy nonsmoking women over 40 years of age may outweigh the possible risks. However, all women, especially older women, are cautioned to use the lowest-dose pill that is effective.

WARNING SIGNALS

If any of these adverse effects occur while you are taking oral contraceptives, call your doctor immediately

- · Sharp chest pain, coughing of blood, or sudden shortness of breath (indicating a possible clot in the lung).
- Pain in the calf (indicating a possible clot in the leg).
- · Crushing chest pain or heaviness in the chest (indicating a possible heart attack).
- Sudden severe headache or vomiting, dizziness or fainting, disturbances of vision or speech, weakness, or numbness in an arm or leg (indicating a possible stroke).
- . Sudden partial or complete toss of vision (indicating a possible clot in the eye).
- Breast lumps (indicating possible breast cancer or fibrocystic disease of the breast; ask your doctor or health-care provider to show you how to examine your breasts).
- . Severe pain or tenderness in the stomach area (indicating a possibly ruptured liver tumor).
- . Difficulty in sleeping, weakness, lack of energy, fatigue, or change in mood (possibly indicating severe depression).

 Jaundice or a yellowing of the skin or eyeballs, accompanied frequently
- by fever, fatigue, loss of appetite, dark-colored urine, or light-colored owel movements (indicating possible liver problems).

SIDE EFFECTS OF ORAL CONTRACEPTIVES

1. Vaginal bleeding

trregular vaginal bleeding or spotting may occur white you are taking the pills. Irregular bleeding may vary from slight staining between menstrual periods to breakthrough bleeding which is a flow much like a regular period. Irregular bleeding occurs most often during the first few months of oralcontraceptive use, but may also occur after you have been taking the pill for some time. Such bleeding may be temporary and usually does not indicate any serious problems. It is important to continue taking your pills on schedule. If the bleeding occurs in more than one cycle or lasts for more than a few days, talk to your doctor or health-care provider.

2. Contact lenses

If you wear contact lenses and notice a change in vision or an inability to wear your lenses, contact your doctor or health-care provider

Oral contraceptives may cause edema (fluid retention) with swelling of the fingers or ankles and may raise your blood pressure. If you experience fluid retention, contact your doctor or health-care provider.

4. Melasma

A spotty darkening of the skin is possible, particularly of the face.

5. Other side effects

Other side effects may include change in appetite, headache, nervousness, depression, dizziness, loss of scalp hair, rash, and vaginal infections.

If any of these side effects bother you, call your doctor or health-care provider. **GENERAL PRECAUTIONS**

1. Missed periods and use of oral contraceptives before or during early pregnancy. There may be times when you may not menstruate regularly after you have completed taking a cycle of pills. If you have taken your pills regularly and miss one menstrual period, continue taking your pills for the next cycle but be sure to inform your health-care provider before doing so. If you have not taken the pills daily as instructed and missed a menstrual period, or if you missed two consecutive menstrual periods, you may be pregnant. Check with your health-care provider immediately to determine whether you are pregnant. Do not continue to take oral contraceptives until you are sure you are not pregnant, but continue to use another method of contraception.

There is no conclusive evidence that oral-contraceptive use is associated with an increase in birth defects, when taken inadvertently during early pregnancy. Previously, a few studies had reported that oral contraceptives might be associated with birth defects, but these studies have not been confirmed. Nevertheless, oral contraceptives or any other drugs should not be used during pregnancy unless clearly necessary and prescribed by your doctor. You should check with your doctor about risks to your unborn child of any medication taken during pregnancy.

2. While breast-feeding

If you are breast-feeding, consult your doctor before starting oral contraceptives. Some of the drug will be passed on to the child in the milk. A few adverse effects on the child have been reported, including yellowing of the skin (jaundice) and breast enlargement. In addition, oral contraceptives may decrease the amount and quality of your milk. If possible, do not use oral contraceptives while breast-feeding. You should use another method of contraception since breast-feeding provides only partial protection from becoming pregnant and this partial protection decreases significantly as you breast-feed for longer periods of time. You should consider starting oral contraceptives only after you have weaned your child completely.

3. Laboratory tests

If you are scheduled for any laboratory tests, tell your doctor you are taking birth-control pills. Certain blood tests may be affected by birth-control pills.

Deaths are birth-related * Deaths are method-related

4. Drug interactions

Certain drugs may interact with birth-control pills to make them less effective in preventing pregnancy or cause an increase in breakthrough bleeding. Such drugs include ritampin, drugs used for epilepsy such as barbiturates (for example, phenobarbital) and phenytoin (Dilantin is one brand of this drug), phenylbutazone (Butazolidin is one brand) and possibly certain antibiotics. You may need to use an additional method of contraception during any cycle in which you take drugs that can make oral contraceptives less effective.

This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted diseases such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B. and syphilis.

HOW TO TAKE THE PILL

This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted diseases such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis.

IMPORTANT POINTS TO REMEMBER

BEFORE YOU START TAKING YOUR PILLS:

1. BE SURE TO READ THESE DIRECTIONS.

Before you start taking your pills.


And

Anytime you are not sure what to do.

- 2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME. If you miss pills you could get pregnant. This includes starting the pack tate. The more pills you miss, the more likely you are to get pregnant.
- 3. MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING. OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST 1-3 PACKS OF PILLS.
- If you feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn't go away, check with your doctor or clinic. 4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT BLEEDING.
- even when you make up these missed pills. On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach.
- 5. IF YOU HAVE VOMITING OR DIARRHEA, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your pills may not work as well. Use a back-up method (such as condoms or foam) until you check with your doctor or clinic.
- 6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control
- 7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFOR-MATION IN THIS LEAFLET, call your doctor or clinic.

BEFORE YOU START TAKING YOUR PILLS

- 1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the same time every day.
- 2. LOOK AT YOUR PILL PACK TO SEE IF IT HAS 21 OR 28 PILLS.
- The 21-pill pack has 21 "active" orange pills (with hormones) to take for 3 weeks, followed by 1 week without pills.
- The 28-pill pack has 21 "active" orange pills (with hormones) to take for 3 weeks, followed by 1 week of "reminder" light-green pills (without hormones). 3. ALSO FIND:
- where on the pack to start taking pills,
- 2) in what order to take the pills (follow the arrows) and
- 3) the week numbers printed on the pack.



4. BE SURE YOU HAVE READY AT ALL TIMES:

ANOTHER KIND OF BIRTH CONTROL (such as condoms or foam) to use as a back-up in case you miss pills. AN EXTRA, FULL PILL PACK.


WHEN TO START THE FIRST PACK OF PILLS:

You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember.

DAY 1 START:

- 1. Pick the day label strip that starts with the first day of your period (this is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins).
- 2. Place this day label strip on the cycle tablet dispenser over the area that has the days of the week (starting with Sunday) printed on the dispensing card.

Pick Correct Day Label THU FRI SAT SUN MON TUE WED



Note: If the first day of your period is a Sunday, you can skip steps #1 and #2.

- 3. Take the first "active" [orange-colored] pill of the first pack during the first 24 hours of your period.
- 4. You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period.

- 1. Take the first 'active' [orange-colored] pill of the first pack on the Sunday after your period starts, even if you are still bleeding. If your
- period begins on Sunday, start the pack that same day 2. Use another method of birth control as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday

(7 days). Condoms or toam are good back-up methods of birth control.

WHAT TO DO DURING THE MONTH

1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS

Do not skip pills even if you are spotting or bleeding between monthly periods or feel sick to your stomach (nausea).

- Do not skip pills even if you do not have sex very often.

 2. WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS: 21 pills. Wait 7 days to start the next pack. You will probably have your
- period during that week. Be sure that no more than 7 days pass between 28 pills: Start the next pack on the day after your last 'reminder' pill. Do
- not wait any days between packs

WHAT TO DO IF YOU MISS PILLS

If you MISS 1 orange 'active' pill:

- 1. Take it as soon as you remember. Take the next pill at your regular time This means you take 2 pills in 1 day.
- 2. You do not need to use a back-up birth-control method if you have sex. If you MISS 2 orange "active" pills in a row in WEEK 1 OR WEEK 2 of your
- 1. Take 2 pills on the day you remember and 2 pills the next day.
- Then take 1 pill a day until you linish the pack.
 You MAY BECOME PREGNANT if you have sex in the 7 days after you. miss pills. You MUST use another birth-control method (such as condoms or foam) as a back-up for those 7 days.

If you MISS 2 orange "active" pills in a row in THE 3rd WEEK:

 Hyou are a Day 1 Starter:

THROW OUT the rest of the pill pack and start a new pack that same day. If you are a Sunday Starter:

Keep taking 1 pill every day until Sunday.

On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day.

- 2. You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant.
- 3 You MAY BECOME PREGNANT it you have sex in the 7 days after you miss pills. You MUST use another birth-control method (such as condoms or foam) as a back-up for those 7 days.
- If you MISS 3 OR MORE orange 'active' pills in a row (during the first 3 weeks): 1. If you are a Day 1 Starter:
- THROW OUT the rest of the pill pack and start a new pack that same day. II you are a Sunday Starter:

Keep taking 1 pill every day until Sunday.

On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day.

- 2. You may not have your period this month but this is expected However, if you miss your period 2 months in a row, call your doctor or
- clinic because you might be pregnant.

 3. You MAY BECOME PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth-control method (such as condoms or foam) as a back-up for those 7 days.

A REMINDER FOR THOSE ON 28-DAY PACKS:

If you forget any of the 7 light-green "reminder" pills in Week 4. THROW AWAY the pills you missed.

Keep taking 1 pill each day until the pack is empty.

You do not need a back-up method if you start your next pack on time.

FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED:

Use a BACK-UP METHOD anytime you have sex.

KEEP TAKING ONE PILL EACH DAY until you can reach your doctor or clinic. Pregnancy due to pill failure

The incidence of pill failure resulting in pregnancy is approximately less than 1.0% if taken every day as directed, but more typical failure rates are less than 3.0%. If failure does occur, the risk to the fetus is minimal. RISKS TO THE FETUS

If you do become pregnant while using oral contraceptives, the risk to the fetus is small, on the order of no more than one per thousand. You should, however, discuss the risks to the developing child with your doctor. Pregnancy after stopping the pill

There may be some delay in becoming pregnant after you stop using oral contraceptives, especially if you had irregular menstrual cycles before you used oral contraceptives. It may be advisable to postpone conception until you begin menstruating regularly once you have stopped taking the pill and desire pregnancy.

There does not appear to be any increase in birth detects in newborn babies when pregnancy occurs soon after stopping the pill Overdosage

Serious ill effects have not been reported following ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea and withdrawal bleeding in females. In case of overdosage, contact your health-care provider or pharmacist. Other information

Your health-care provider will take a medical and family history before prescribing oral contraceptives and will examine you. The physical examination may be delayed to another time if you request it and the health-care provider believes that it is appropriate to postpone it. You should be reexamined at least once a year. Be sure to inform your health care provider if there is a family history of any of the conditions listed previously in this leaflet. Be sure to keep all appointments with your health-care provider, because this is a time to determine if there are early signs of side effects of oral-contraceptive use,

Do not use the drug for any condition other than the one for which it was prescribed. This drug has been prescribed specifically for you; do not give it to others who may want birth-control pills.

HEALTH BENEFITS FROM ORAL CONTRACEPTIVES

In addition to preventing pregnancy, use of oral contraceptives may provide certain benefits. They are:

· Menstrual cycles may become more regular.

- Blood flow during menstruation may be lighter, and less iron may be lost. Therefore, anemia due to iron deficiency is less likely to occur Pain or other symptoms during menstruation may be encountered less
- frequently. Ovarian cysts may occur less frequently.

Ectopic (tubal) pregnancy may occur less frequently.

. Noncancerous cysts or lumps in the breast may occur less frequently. Acute petvic inflammatory disease may occur less frequently.

- Oral-contraceptive use may provide some protection against developing two forms of cancer: cancer of the ovaries and cancer of the lining of
- If you want more information about birth-control pills, ask your doctor or pharmacist. They have a more technical featlet called the Professional Labeling which you may wish to read.

DURAMED PHARMACEUTICALS, INC. CINCINNATI. OH 45213 USA

100397

ISS. 09/00

Aviane" -21 TABLETS

(levonorgestrel and ethinyl estradic-

Patients should be counseled that this product does not pro intection (AIDS) and other sexually transmitted diseases.

R only

Description
21 orange active tablets each containing 0.10 mg of levonorgestrel. d(-)-138-ethyl21 orange active tablets each containing 0.10 mg of levonorgestrel. d(-)-138-ethyl102 mg of ethinyl estradiol. 170-ethyl-1.38 (190-ethyl-1.37 hg-loi). The
102 mg of ethinyl estradiol. 170-ethyl-1.38 (190-ethyl-1.38 hg-loi). Be Alumnum Lake, hydrosnachive ingredients present are: FD&C Yellow in 6. Alumnum Lake, hydrosypropyl methylceilulose, lactose monohydrate. nagnesum stearch; microcrystabline cellulose. Doytethylene glycol, pregelatinized starch, sodium starch glycolate
and titanium dioxide.

CaHi.

MF: C21H2802

Ethinyl Estradiol

MF: C20H24O2

MW 296 40

Clinical Pharmacotory


Combination oral contraceptives act by suppression of gonadotropins. Although the pimary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation).

PHARMACOKINETICS

to 21 (Figure 1).

FIGURE 1

Mean (SE) tevonorgestret and ethinyl estradiol serum concentrations in 22 subjects receiving 100 µg levonorgestret and 20 µg ethinyl estradiol



ie i provides a summary of levonorgiestrei and ethinyl estradiol pharmacolónetic parameters TABLE 1: MEAN (SD) PHARMACOKINETIC PARAMETERS OF levonorigestrel and ethinyl estradiol, 0.10 mg/0.02 mg tablets OVER A 21-DAY DOSING PERIOD

	C ^{MASK}	Timax	AUC no-h/ml.	CL/F mt/hAka	VXz/F L/Kg	nmol/L
Day 1 6 21	2.75 (0.58) 4.52 (1.79) 6.00 (2.65)	1.6 (0.9) 1.5 (0.7) 1.5 (0.5)	35.2 (12.8) 46.0 (18.8) 68.3 (32.5)	53 7 (20.8) 40.8 (14.5) 28 4 (10.3)	2.66 (1.09) 2.05 (0.86) 1.43 (0.62)	57 (18) 81 (25) 93 (40)

	Linbound Levenorgestral					6.6/
		h	pg=h/mL	L/M/co	L/kg	tu %_
	pg/ml.	16 (0.9)	664 (201)	2.79 (0.97)	135.9 (41.8)	1.92 (0.30)
1	51.2 (12.9)		794 (240)	2.24 (0.59)	112 4 (405)	1.80 (0.24)
6	77.9 (22.0)	1.5 (0.7)	1177 (452)	1.57 (0.49)	786 (297)	1 78 (0 19)
	102 E (26 Q)	15(05)	11// (452)	1,37 10 757		

			ETHINA PERSONO			
	po/ml.	h_	pg-h/mi,	<u>m),/h/kn</u>	<u> </u>	
	62.0 (20.5)	1.5 (0.5)	663 (227)	567 (204)	14.3 (3.7)	
1.	76.7 (29.9)	13(07)	604 (231)	610 (196)	15 5 (4.D)	
6	82.3 (33.2)	1.4 (0.6)	776 (308)	486 (179)	12.4 (4.1)	
21						

Time (bours) > Day 1 • Day 6 ▲ Day 21

Time (hours)

> Day 1 • Day 6 • Day 21

Ethinyl Estradiol

.

Table I provides a summary of levonorgestres and ethniyl estradiol pharmacolonetic parameters TABLE 1: MEAN (SD) PHARMACOKINETIC PARAMETERS OF levonorgestrel and ethinyl estradiol, 0.10 mg/0.02 mg tablets OVER A 21-DAY DOSING PERIOD

Levonorgestre!

Day	C _{LUS}	I _{man}	AUC ng-h/mi,	CL.F mL/ty/kg	VAZF LAG	SHBG nmol1
1	2 75 (0.88)	16(09)	35.2 (12.8)	53 7 (20 8:	2.66 (1.09)	57 (18-
6	4.52 (1.79)	1.5 (0.7)	460(188)	40 8 (14 5)	205 (0.86)	81 (25-
21	6.00 (2.65)	15 (05)	68.3 (32.5)	28 4 (10 3)	1.43 (0.62)	93 (40)

5 (05)	68.3 (32.5)	284(103)	1.43 (0.62)
Und	ound Levonorge	SUR!	

pg/mt	<u>· h</u>	pgrhmi	L/h/hg	LAC	ħυ',
51.2 (12.9)	16(09:	654 (201)	2.79 (0.97)	135 9 (41 8)	1.92 (0.3G)
77.9 (22.0)	15 (07)	794 (240)	2.24 (0.59	112 4 (40 5)	180 (024
103 6 (36.9)	15(05)	1177 (452)	1.57 (0.49-	786 (297)	1 78 (0 19-
	51.2 (12.9) 77.9 (22.0)	51.2 (12.9) 1 6 (0.9) 77.9 (22.0) 1.5 (0.7)	51.2 (12.9) 1.6 (0.9) 654 (201) 77.9 (22.0) 1.5 (0.7) 794 (240)	512 (12.9) 16 (0.9) 654 (201) 2.79 (0.97) 77.9 (22.0) 1.5 (0.7) 794 (240) 2.24 (0.59)	512 (12.9) 16 (0.9) 654 (201) 2.79 (0.97) 135 9 (41.6) 77.9 (22.0) 15 (0.7) 794 (240) 2.24 (0.59) 112 4 (40.5)

			Ethinyl Estradio	ı		
	po/ml	h	po=t/mL	mL/N/Lg	L/kg	
1	62.0 (20.5)	1.5 (0.5)	653 (227)	567 (204)	143 (37)	
6	767 (29.9)	1.3 (07)	604 (231)	610 (196)	155140	
21	82.3 (33.2)	1.4 (0.6)	776 (308)	486 (179)	12 4 (4 1)	

Levonorgestrel in serum is primaziiv hound to SHBG. Ethinyl estradiol is about plasma albumin. Ethinyl estradiol does not bind to SHBG, but induces SHBG synthesis. Metabolism

Metabolisme: The most important metabolic pathway occurs in the reduction of the Δ4-3-ox o group and hydroxylation at positions Σπ. 1β, and 16β, followed by conjugation. Most of the metabolites that circulate in the blood are suitates of 3α.5β-tetralydro-levioningestiet, while excretion occurs predominantly in the form of plucuronides. Some of the parent levionorgestrel also circulates as 17/β-suitate Metabolic clearance rates may differ among individuals by severalfold, and fris may account in part for the wide variation observed in levionorgestrel concentrations among users.

Ethinyi estration: Oxochrome P450 enzymes (CYP3A4) in the liver are responsible for the 2-hydroxylation that is the major oxidative reaction. The 2-hydroxy metabolite is further transformed by methylation and glucuronidation prior to urmary and fecal excretion. Levels of Oxochrome P450 (CYP3A) vary widely among individuals and can explain the variation in rates of ethinyi estradiol 2-hydroxylation Ethinyi estradiol is excreted in the unner and feces as glucuronide and sulfate conjugates, and undergoes enterohepatic circulation.

Excretion

The elimination half-life for levonorgestrel is approximately 36 x 13 hours at steady.

The elimination half-life for levonorgestrel is approximately 36 \pm 13 hours at steady state.

Levonorgestrel and its metabolites are primarily excreted in the urine (40% to 68%) and about 16% to 48% are excreted in feces. The elimination half-life of sthinyl estradiol is 18 ± 4.7 hours at sleady state.

Race

Based on the pharmacokinetic study with levonorgestrel and ethinvi estradiol 0.10 mg/0.02 mg tablets, there are no apparent differences in pharmacokinetic parameters among women of different races. Hepatic Insufficiency No formal studies have evaluated the effect of hepatic disease on the disposition of Aviane** (evonorgestrel and ethinyl estradiol) tablets. However, steroid hormones may be poorly melabolized in patients with impaired liver function. Renal Insufficiency

No formal studies have evaluated the effect of renal disease on the disposition of Aviane.

Drug-Drug Interactions

Interactions between ethinyl estradiol and other drugs have been reported in the interature.

- Interactions with Absorption: Diarrhea may increase gastrointestinal motility and reduce hormone absorption. Similarly, any drug which reduces gut transit time may reduce hormone concentrations in the blood. Interactions with Metabolism:

- Interactions with Metabolism:

 Gastrointestral wall: Sulfation of ethinyl estradiol has been shown to occur in the gastrointestral (6) wall. Interfere, drugs which act as competitive inhibitors for sulfation in the Gl wall may increase ethinyl estradiol bioavariability (e.g., ascorbic acid).

 Hepatic metabolism: Interactions can occur with drugs that induce microsomal enzymes which can decrease ethinyl estradiol concentrations (e.g., rifampin, barbiturates, phenylbulazone, phenylon, gnsediulvin).

 Interference with Enterohepatic Circulation: Some clinical reports suggest that enterohepatic circulation of estrogens may decrease when certain antibioric agents are given, which may reduce ethinyl estradiol concentrations (e.g., amplicialin, letracycline).

 Interference in the Metabolism of Other Drugs: Ethinyl estradiol may interfere with the metabolism of other drugs by inhibiting hepatic microsomal enzymes or by inducing hepatic drug conjugation, particularly glucuromodation, Accordingly, plasma and tissue concentrations may either be increased or decreased, respectively (e.g., cyclosporin, theophylline)

 cations and Usage

Indications and Usage

Indications and Usage
Oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.
Oral contraceptives are highly effective. Table II lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and Norplant. System, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.

TABLE II: PERCENTAGE OF WOMEN EXPERIENCING AN UNINTENDED PREGNANCY DURING THE FIRST YEAR OF USE OF A CONTRACEPTIVE METHOD

Method	Perfect Use	Typical Use
Norplant' System (6 capsules)	0.1	0.1
Male sterilization	0.1	0.15
Female sterilization	04	0.4
Depo-Provera: (injectable progestoge	n) 0.3	0.3
Oral contraceptives		3
Combined	0.1	NA
Progestin only	0.5	- NA
IUD		
Progesterone	1.5	20
Copper T 380A	0.6	0.8
Condom (male) without spermicide	3	12
(female) without spermicide	5	21
Cervical cap	-	• '
Nulliparous women	9	18
Parous women	26	36
Diaphragm with spermicidal		30
cream or jelly	6	18
Spermicides alone	•	70
(foam, creams, jellies, and vagina	n!	
SUDDOS(tories)	. 6	21
Periodic abstinence (all methods)	1-9*	20
Withdrawal	4	19
Vo contraception (planned pregnancy)		85

*Depending on method (calendar, ovulation, symptothermal, post-ovulation) Adapted from Hatcher RA et al. Contraceptive Technology, 16th Revised Edition New York, NY: Irvington Publishers, 1994

S iol tablets) protect against HIV

DURAMED PHAR Mtd. by: CINCINNATI, OH

APR 30

in a clinical trial with levonorgestrel and ethinyl estradiol 0.10 mg/0.02 mg tablets. in a clinical trial with levonorgestricl and ethinyl estractiol 0.10 mg/0.02 mg tablets. 1,477 subjects had 7.720 cycles of use and a total of 5 pregnancies were reported. This represents an overall pregnancy rate of 0.84 per 100 woman-years. This rate includes patients who did not take the drug correctly. One or more pilis were missed during 1,479 (18.8%) of the 7.870 cycles; thus all tablets were taken during 6.391 (81.2%) of the 7.870 cycles. Of the total 7.870 cycles. 3 1012* of 150-cycles were excluded from the calculation of the Pearl index due to the use of back-ween transfering and/or mission 3 or more consecutive pilis. up contraception and/or missing 3 or more consecutive pills.

Oral contraceptives should not be used in women with any of the following conditions: Thrombophlebitis or thromboembolic disorders

Infollophicans of unontocentonic usorones.

A past history of deep-ven thrombophlebits or thromboembolic disorders Cerebrovascular or coronary artery disease Known or suspected carcinoma of the breast

Carcinoma of the endometrium or other known or suspected estrogen-dependent

Carcinolla of the Endomenton neoplasia Undiagnosed abnormal genital bleeding Cholestatic jaundice of pregnancy or jaundice with prior pill use Hepatic adenomas or carcinomas Known or suspected pregnancy

Cigarette smoking increases the risk of serious cardiovascular side effects from oral-contracaptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in neary screening (13 or arone organisms per eary) and is gains marked in women over 35 years of age. Women who ase oral contraceptives should be strongly advised not to smoke.

The use of oral contraceptives is associated with increased risks of several serious conditions including myocardial intarction, thromboembolism, stroke, hepatic neoconditions including myocardial intarction, thromboembolism, stroke, hepatic neo-pasia, galibladder disease, and hypertension, although the risk of serious morbid-ity or mortality is very small in healthy women without underlying risk factors. The nisk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, obesity and dia-

Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks.

The information contained in this package insert is principally based on studies The information contained in this package insert is principally based on studies carried out in patients who used oral contraceptives with higher formulations of estrogens and progestogens than those in common use flody. The effect of long-term use of the oral contraceptives with lower doses of both estrogens and progestogens remains to be determined.

progestogens remains to be determined.


Throughout this labeling, epidemiological studies reported are of two types; retrospective or case control studies and prospective or cohort studies. Case control studies provide a measure of the relative risk of disease, namely, a ratio of the incidence of a disease among oral-contraceptive users to that among nonusers. The relative risk does not provide information on the actual clinical occurrence of a disease. Cohort studies provide a measure of attributable risk, which is the difference in the incidence of disease between oral-contraceptive users and nonusers. The attributable risk does provide information about the actual occurrence of a disease in the population. For further information, the reader is referred to a text on epidemiological methods.

1. THROMBOEMBOLIC DISORDERS AND OTHER VASCULAR PROBLEMS

a. Myocardial Infarction

An increased risk of myocardial infarction has been attributed to oral-contraceptive use This risk is primarily in smokers or women with other underlying risk factors for coronary-artery disease such as hypertension, hypercholesterotemia, morbid obesity, and diabetes. The relative risk of heart attack for current oral-contraceptive users has been estimated to be two to six. The risk is very low under the age of 30. Smoking in combination with oral-contraceptive use has been shown to contribute substantially to the incidence of myocardial infarction in women in their mid-thir-ties or older with smoking accounting for the majority of excess cases. Mortality rates associated with circulatory disease have been shown to increase substantially in smokers over the age of 35 and nonsmokers over the age of 40 (Table III) among women who use oral contraceptives.

CIRCULATORY DISEASE MORTALITY RATES PER 100.000 WOMAN YEARS BY AGE. SMOKING STATUS AND ORAL-CONTRACEPTIVE USE



Oral contraceptives may corr pound the effects of well-known risk factors, such as hypertension, diabetes, hyper-lipidemias, age and obesity. In particular, some progestogens are known to decrease HDL cholesterol and cause olucose intolerance, white estrogens
may create a state of hyperinsulmism. Oral contraceptives have been shown to increase blood pressure among users (see section 9 in "Warnings"). Similar effects on risk factors have been associated with an increased risk of heart disease. Oral contraceptives must be with caution in women with cardiovascular disease risk factors.

h Thromboembolism

smokers over the age of 35 and nonsmokers over the age of 40 (Table III) and women who use oral contraceptives.

CIRCULATORY DISEASE MORTALITY RATES PER 100,000 WOMAN YEARS BY AGE, SMOKING STATUS AND ORAL-CONTRACEPTIVE USE




TABLE III. (Adapted from P.M. Layde and V. Beral, well established. Case control Lancet, 1:541-546, 1981)

stylings have found, the rela-

pound the effects of wellknown risk factors, such as hypertension, diabetes, hypertipidemias, age and obesity. In particular, some progestogens cholesterol and cause discose intolerance, while estrogens may create a state of hyperinhave been shown to increase blood pressure among users (see section 9 in "Warrings"). Similar effects on risk factors have been associated with an increased risk of heart disease Oral contraceptives must be used with caution in women with cardiovascular disease nsk factors

b. Thromboembolism
An increased risk of thromboembolic and thrombotic disease associated with this use of oral contraceptives is well established. Case control studies have found the rela-

tive risk of users compared to non-users to be 3 for the first episode of superficial venous thrombosis. 4 to 11 for deep-vein thrombosis or pulmonary embotism, and 15 to 6 for women with predisposing conditions for venous thromboembolic disease. Cohort studies have shown the relative risk to be somewhat lower, about 3 for new cases and about 4.5 for new cases requiring hospitalization. The risk of thromboembolic disease due to oral contraceptives is not retailed to length of use and disappears after pill use is stopped.

A two- to four-fold increase in relative risk of postoperative thromboembolic complications has been reported with the use of oral contraceptives. The relative risk of venous thrombosis in women who have predisposing conditions is twice that of women without such medical conditions. It leasible, oral contraceptives should be discontinued at least four weeks prior to and for two weeks after elective surgery of a type associated with an increase in risk of thromboembolism and during and following protonged immobilization. Since the immediate post-partum period is also associated with an increased risk of thromboembolism, oral contraceptives should be started no earlier than four to six weeks after delivery in women who elect not to breast-leed, or a midtimester pregnancy termination.

c. Cerebrovascular diseases

Oral contraceptives have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (-35 years), hypertensive women who also smoke. Hypertension was found to be a risk factor for both users and nonusers, for both types of strokes, while smoking interacted to increase the risk for hemorrhagic strokes.

In a large study, the relative risk of thrombotic strokes has been shown to range from 3 for normatensive users to 14 for users with severe hypertension. The relative risk of hemorrhagic stroke is reported to be 1.2 for nonsmokers who used oral contraceptives, 2.6 for smokers who did not use oral contraceptives, 7.6 for smokers who used oral contraceptives, 1.8 for normotensive users and 25.7 for users with severe hypertension. The attributable risk is also greater in older women.

d. Dose-related risk of vascular disease from oral contraceptives

A positive association has been observed between the amount of estrogen and progestogen in oral contraceptives and the risk of vascular disease. A decline in serum high-density (poportiens (HDL) has been reported with many progestational agents. A decline in serum high-density (poportiens has been associated with an increased incidence of ischemic heart disease. Because estrogens increase HDL choiesterol, the net effect of an oral contraceptive depends on a balance achieved between doses of estrogen and progestogen and the nature and absolute amount of progestogen used in the contraceptive. The amount of both hormones should be considered in the choice of an oral contraceptive.

Minimizing exposure to estrogen and progestogen is in keeping with good principles of therapeutics. For any particular estrogen/progestogen combination, the dosage regimen prescribed should be one which contains the least amount of estrogen and progestogen that is compatible with a low failure rate and the needs of the individual patient. New acceptors of oral-contraceptive agents should be started on preparations containing less than 50 mcg of estrogen.

e. Persistence of risk of vascular disease

There are two studies which have shown persistence of risk of vascular disease to ever-users of oral contraceptives. In a study in the United States, the risk of developing myocardial infarction after discontinuing oral contraceptive persists for all least 9 years for women 40-49 years who had used oral contraceptives for five or more years, but this increased risk was not demonstrated in other age groups. In another study in Great Britain, the risk of developing cerebrovascular disease persisted for at least 6 years after discontinuation of oral contraceptives, although excess risk was very small. However, both studies were performed with oral contraceptive formulations containing 50 micrograms or higher of estipodens.

2. ESTIMATES OF MORTALITY FROM CONTRACEPTIVE USE

One study gathered data from a variety of sources which have estimated the mortality rate associated with different methods of contraception at different ages (Table IV). These estimates include the combined risk of death associated with contraceptive methods plus the risk attributable to pregnancy in the event of method tailure. Each method of contraception has its specific benefits and risks. The study concluded that with the exception of oral-contraceptive users 35 and older who smoke and 40 and older who do not smoke, mortality associated with all methods of birth control is less than that associated with childbirth. The observation of a possible increase in risk of mortality with age for oral-contraceptive users is based on data gathered in the 1970's—but not reported until 1983. However, current chinical practice involves the use of lower estrogen dose formulations combined with careful restriction of oral-contraceptive use to women who do not have the various risk factors listed in this labeling.

Because of these changes in practice and, also, because of some limited new data which suggest that the risk of cardiovascular disease with the use of oral contraceptives may now be less than previously observed, the Fertility and Material Health Drugs Advisory Committee was asked to review the topic in 1989. The Committee concluded that although cardiovascular disease risks may be increased with oral-contraceptive use after age 40 in healthy nonsmoking women (even with the newer low-dose formulations), there are greater potential health risks associated with pregnancy in older women and with the alternative surgical and medical procedures which may be necessary if such women do not have access to effective and acceptable means of contraception.



HARMACEUTICALS, INC. 1-OH 45213 USA

ISS. 09/00

Therefore, the Committee recommended that the benefits of oral-contraceptive use by healthy nonsmoking women over 40 may outweigh the possible risks, O' course, older women, as all women who take oral contraceptives, should take the lowest possible dose formulation that is effective.

.

TABLE IV: ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS
ASSOCIATED WITH CONTROL OF FERTILITY PER 100.000 NONSTERILE WOMEN.
BY FERTILITY-CONTROL METHOD AND ACCORDING TO AGE

15-19	20-24	25-29	30-34	35-39	40-44
7.0	7.4	9 1	14.8	25 7	28.2
0.3	0.5	0.9	1.9	13.8	31.6
2.2	3 4	6.6	13.5	51.1	117.2
0.8	0.8	10	1.0	1.4	1.4
1,1	1.6	0.7	0.2	0.3	0 4
1.9	1.2	1.2	1.3	2.2	2.8
2.5	1.6	1.6	1 7	2.9	3.6
	7.0 0.3 2.2 0.8 1.1 1.9	0.3 0.5 2.2 3.4 0.8 0.8 1.1 1.6 1.9 1.2	7.0 7.4 91 0.3 0.5 0.9 2.2 34 6.6 0.8 0.8 10 1.1 1.6 0.7 1.9 1.2 1.2	7.0 7.4 91 14.8 0.3 0.5 0.9 1.9 2.2 34 6.6 13.5 0.8 0.8 1.0 1.0 1.1 1.6 0.7 0.2 1.9 1.2 1.2 1.3	7.0 7.4 91 14.8 257 0.3 0.5 0.9 1.9 13.8 2.2 34 6.6 13.5 51.1 0.8 0.8 1.0 1.0 1.4 1.1 1.6 0.7 0.2 0.3 1.9 1.2 1.2 1.3 2.2

Deaths are birth-related

Adapted from H.W. Ory. Family Planning Perspectives. 15:57-63.1983.

3. CARCINOMA OF THE REPRODUCTIVE ORGANS

Numerous epidemiological studies have been performed on the incidence of breast, endometrial, ovarian and cervical cancer in women using oral contraceptives. The overwhelming evidence in the Interature suggests that use of oral contraceptives is not associated with an increase in the risk of developing breast cancer, regardless of the age and parity of first use or with most of the marketed brands and doses. The Cancer and Steroid Hornone (CASH) study also showed no latent effect on the risk of breast cancer for at least a decade following tring-term use. A few studies have shown a slightly increased relative risk of developing breast cancer, although the methodology of these studies, which included differences in examination of users and nonusers and differences in age at start of use, has been questioned.

Some studies suggest that oral-contraceptive use has been associated with an increase in the risk of cervical intraepithehal neoplasia in some populations of women. However, there continues to be controversy about the extent to which such lindings may be due to differences in sexual behavior and other factors.

In spite of many studies of the relationship between oral-contraceptive use and breast and cervical cancers, a cause-and-effect relationship has not been estab-

4. HEPATIC NEOPLASIA

Benign hepatic adenomas are associated with oral-contraceptive use, although the incidence of these benign tumors is rare in the United States, indirect calculations have estimated the altibutable risk to be in the range of 3.3 cases/100.000 for users, a risk that increases after four or more years of use. Rupture of rare, benign, hepatic adenomas may cause death through intra-abdominal hemorrhage.

Studies from Britain have shown an increased risk of developing hepatocellular carcinoma in tong-term (>8 years) oral-contraceptive users. However, these cancers are extremely rare in the U.S. and the attributable risk (the excess incidence) of liver cancers in oral-contraceptive users approaches tess than one per million users.

5. OCULAR LESIONS

There have been clinical case reports of retinal thrombosis associated with the use of oral contraceptives. Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of propriosis or diplopia; papilledema; or retinal vascular lesions. Appropriate diagnostic and therapeutic measures should be undertaken immediately.

6. ORAL-CONTRACEPTIVE USE BEFORE OR DURING EARLY PREGNANCY

Extensive epidemiological studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy. Studies also do not suggest a teratogenic effect, particularly in so far as cardiac anomalies and himb-reduction defects are concerned, when taken inadvertently during early pregnancy.

The administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy. Oral contraceptives should not be used during pregnancy to treat threatened or habitual abortion.

It is recommended that for any patient who has missed two consecutive periods, pregnancy should be ruled out before continuing oral-contraceptive use. If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period. Oral-contraceptive use should be discontinued if pregnancy is contirmed.

7. GALLBLADDER DISEASE

7. GALLBLADDEN DISEASE Earlier studies have reported an increased litetime relative risk of galibladder surgery in users of oral contraceptives and estrogens. More recent studies, however, have shown that the relative risk of developing galibladder disease among oral-contraceptive users may be minimal. The recent findings of minimal risk may be related to the use of oral-contraceptive formulations containing lower hormonal doses of estrogens and progestogens.

8. CARBOHYDRATE AND LIPID METABOLIC EFFECTS

Oral contraceptives have been shown to cause glucose intolerance in a significant percentage of users. Oral contraceptives containing greater than 75 micrograms of estrogens cause hypennsulnism, while lower doses of estrogen cause less glucose intolerance. Propestogens increase insulin secretion and create insulin resistance, this effect varying with different progestational agents. However, in the non-diabetic woman, oral contraceptives appear to have no effect on fasting blood glucose. Because of these demonstrated effects, prediabetic and diabetic women should be carefully observed white taking oral contraceptives.

A small proportion of women will have persistent hypertriolyceridemia while on the

^{..} Deaths are method-related

The administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy. Oral contraceptives should not be used during pregnancy to treat threatened or habitual abortion

It is recommended that for any patient who has missed two consecutive genoric pregnancy should be ruled out before continuing oral-contraceptive use. If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period. Oral-contraceptive use should be discontinued if pregnancy is confirmed.

7. GALLEL ANDER DISEASE

Earlier studies have reported an increased lifetime relative risk of gallbladder surgery in users of oral contraceptives and estrogens. More recent studies, how-ever, have shown that the relative risk of developing galibadder disease among oral-contraceptive users may be minimal. The recent findings of minimal risk may be related to the use of oral-contraceptive formulations containing lower hormonal doses of estrogens and progestogens.

8. CARBOHYDRATE AND LIPID METAROLIC FEFFCTS

Oral contraceptives have been shown to cause glucose intolerance in a significant percentage of users. Oral contraceptives containing greater than 75 micrograms of estrogens cause hypennsulinism, while lower doses of estrogen cause less glucose intoterance. Procestocens increase insulin secretion and create insulin resistance, this effect varying with different progestational agents. However, in the nondiabetic woman, oral contraceptives appear to have no effect on fasting blood glucose. Because of these demonstrated effects, prediabetic and diabetic women should be carefully observed while taking oral contraceptives.

A small proportion of women will have persistent hypertriglyceridemia while on the pill. As discussed earlier (see "Warnings" 1a. and 1d.), changes in serum trighyc-erides and lipoprotein levels have been reported in oral-contraceptive users.

9. ELEVATED BLOOD PRESSURE

An increase in blood pressure has been reported in women taking oral contracep-tives and this increase is more likely in older oral-contraceptive users and with con-tinued use. Data from the Royal College of General Practitioners and subsequent randomized trials have shown that the incidence of hypertension increases with increasing quantities of progestogens.

Women with a history of hypertension or hypertension-related diseases, or renal disease should be encouraged to use another method of contraception. If women with hypertension elect to use oral contraceptives, they should be monitored close-by and if significant elevation of blood pressure occurs, oral contraceptives should be discontinued. For most women, elevated blood pressure will return to normal after stopping oral contraceptives: and there is no difference in the occurrence of hypertension among ever- and never-users.

10. HEADACHE

The onset or exacerbation of migraine or development of headache with a new pattern that is recurrent, persistent or severe requires discontinuation of oral contraceptives and evaluation of the cause

11. BLEEDING IRREGULARITIES

through bleeding and spotting are sometimes encountered in patients on oral contraceptives, especially during the first three months of use. The type and dose of progestogen may be important. Nonhormonal causes should be considered and adequate diagnostic measures taken to rule out malignancy or pregnancy in the event of breakthrough bleeding, as in the case of any abnormal vaginal bleeding, it pathology has been excluded, time or a change to another formulation may solve the problem. In the event of amenorihea, pregnancy should be ruled out.

Some women may encounter post-pill amenormea or oligomenormea, especially when such a condition was preexistent.

Patients should be counseled that this product does not protect against HIV intection (AIDS) and other saxually trans-

1. PHYSICAL EXAMINATION AND FOLLOW-UP

A periodic history and physical examination is appropriate for all women, including women using oral contraceptives. The physical examination, however, may be deterred until after initiation of oral contraceptives if requested by the woman and judged appropriate by the clinician. The physical examination should include special reference to blood pressure, breasts, abdomen and pelvic organs, including cervical cytology, and relevant laboratory tests. In case of undiagnosed, persistent or recurrent abnormal vaginal bleeding, appropriate diagnostic measures should be conducted to rule out mangnancy. Women with a strong tamily history of breast cancer or who have breast nodules should be monitored with particular care

Women who are being treated for hyperlipidemias should be followed closely if they elect to use oral contraceptives. Some progestogens may elevate LDL levels and may render the control of hyperlipidemias more difficult.

3. LIVER FUNCTION

If jaundice develops in any woman receiving such drugs, the medication should be discontinued. Steroid normones may be poorly metabolized in patients with

4. FLUID RETENTION

Oral contraceptives may cause some degree of fluid retention. They should be prescribed with caution, and only with careful monitoring, in patients with conditions which might be aggravated by fluid retention.

5. EMOTIONAL DISORDERS

Patients becoming significantly depressed while taking oral contraceptives should stop the medication and use an alternate method of contraception in an attempt to determine whether the symptom is drug retated. Women with a history of depression should be carefully observed and the drug discontinued if depression recurs

6. CONTACT LENSES

Contact-less wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.

7. DRUG INTERACTIONS

Reduced efficacy and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin. A similar association, though less marked, has been suggested with barbiturates, phenyibutazone, phenytoin, and possibly with griseotulvin, ampicillin, and tetracyclines.

8 INTERACTIONS WITH LABORATORY TESTS

Certain endocrine- and inver-function tests and blood components may be affected by oral contraceptives:

- a. Increased prothrombin and factors VII. VIII. IX. and X; decreased ambihrombin
- a. Increased prothrombin and tactors vii. Viii. (A. and A. decreased analous) as increased norepinephrine induced platelet aggregability.
 b. Increased thyroid-binding globulin (FBG) leading to increased circulating total thyroid-binding globulin (FBG) leading to increased circulating total thyroid-binding same savered by protein-bound iodine (FBI). T4 by column or by radioimmunoassay Free T3 resin uptake is decreased, reflecting the elevated TBG; tree T4 concentration is unaltered.
- c. Other binding proteins may be elevated in serum.
 d. Sex-hormone binding globulins are increased and result in elevated levels of total circulating sex steroids; however, free or biologically active levels remain
- Triglycerides may be increased. f. Glucose tolerance may be decreased.
- g. Serum folate levels may be depressed by oral-contraceptive therapy. This may

be of clinical significance if a woman becomes pregnant shortly after discontinu ing oral contraceptives
9. CARCINOGENESIS See "Warnings" section. 10. PREGNANCY Pregnancy Category X. See 'Contraindications' and 'Warnings' sections.

11. NURSING MOTHERS

Small amounts of oral-contraceptive steroids have been identified in the milk of oral-contraceptive steroids have been reported, including inquintiers, and a few adverse effects on the child have been reported, including jaundice and breast enlargement, in addition, oral contraceptives given in the postparium period may interfere with lactation by decreasing the quantity and updates mik. It possible, the nursing mother should be advised out to use oral confraceptives but to use other forms of confraception until she has committed.

INFORMATION FOR THE PATIENT See Patient Labeling Printed Below

Adverse Reactions

An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see "Warnings" section)
Thrombophiebitis

Arterial thromboembolism Pulmonary empolism

Myocardial infarction

Cerebral hemorrhane Cerebral thrombosis

Hypertension

Galibladder disease

Hepatic adenomas or benign liver tumors

There is evidence of an association between the following conditions and the use of oral contraceptives, although additional confirmatory studies are needed. Mesenteric thrombosis

Retinal thrombosis

The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug related.

Nausea Vorniting

Gastrointestinal symptoms (such as abdominal cramps and bloating) Breakthrough bleeding

Spotting Change in menstrual flow

Amenormea

Temporary infertility after discontinuation of treatment

Edema

Melasma which may persist Breast changes; tenderness, enlargement, secretion

Change in weight (increase or decrease) Change in cervical erosion and secretion

Diminution in sectation when given immediately postpartum Cholestatic joundice

Migraine Rash (allergic)

Mental degression

Reduced tolerance to carbohydrates

Vaginal candidiasis Change in corneal curvature (steepening) Intolerance to contact lenses

The following adverse reactions have been reported in users of oral contraceptives and the association has been neither confirmed nor refuted Premenstrual syndrome

Cataracts Optic neuritis

Changes in appetite Cystitis-like syndrome

Headache

Nervousness Dizziness

Hirsulism Loss of scalo hair

Erythema nodosum

Hemorrhagic eruption Vacinitis

Impaired renal function

Hemolytic uremic syndrome Budd-Chian syndrome

Changes in libido

Colitis

Overdosane

Senous ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea, and with-drawal bleeding may occur in females.

ontraceptive Health Benefits

The following noncontraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies which largely utilized oral-con-traceptive formulations containing doses exceeding 0.035 mg of ethinyl estradiol or 0.05 mg of mestranol.

Effects on menses:

Increased menstrual cycle regularity
Decreased blood loss and decreased incidence of iron-deficiency anemia

Decreased incidence of dysmenorrhea

Effects related to inhibition of ovulation: Decreased incidence of functional ovarian cysts

Decreased incidence of ectopic pregnancies

Effects from long-term use: Decreased incidence of libroadenomas and librocystic disease of the breast Decreased incidence of acute pelvic inflammatory disease Decreased incidence of endometrial cancer Decreased incidence of ovarian cancer

To achieve maximum contraceptive effectiveness. Aviane™ (levonorgestre) and to achieve maximum contraceptive effectiveness, where the additional estimated estraction 0.10 mg/0.20 mg) tablets must be taken exactly as directed and at intervals not exceeding 24 hours. The dispenser should be kept in the wallet submit of to avoid possible lading of the news. If the pills fade, patients should continue Headache

Nervousness

Dizziness Hirsubsm

Loss of scalp hair

Erythema multiforme

Erythema nodosum

Hemorrhagic eruption

Vaginnis

Porphyria Impaired renal function Hemolytic uremic syndrome

Budd-Chian syndrome Acne

Changes in libido Colars

Overdozage

of oral contraceptives by young children. Overdosage may cause nausea, and with-drawal bleeding may occur in females. Senous ill effects have not been reported following acute ingestion of large doses

Noncontraceptive Health Benefits

The following noncontraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies which largely utilized oral-con-traceptive formulations containing doses exceeding 0.035 mg of ethinyl estradiol or 0.05 mg of mestranol.

Effects on menses:

Increased menstrual cycle regularity

Decreased blood loss and decreased incidence of iron-deliciency anemia

Decreased incidence of dysmenorrhea

Effects related to inhibition of ovulation;

Decreased incidence of functional ovarian cysts Decreased incidence of ectopic pregnancies

Effects from long-term use:

Decreased incidence of tibroadenomas and tibrocystic disease of the breast

Decreased incidence of acute pelvic inflammatory disease

Decreased incidence of endometrial cancer

Decreased incidence of ovarian cancer

Dosage and Administration

To achieve maximum contraceptive effectiveness, Aviane " (fevonorgestre) and ethinyl estradiol 0.10 mg/0.02 mg) tablets must be taken exactly as directed and at intervals not exceeding 24 hours. The dispenser should be kept in the wallet supplied to avoid possible fading of the pills. If the pills lade, patients should continue to take them as directed.

The dosage of Aviane™ -21 is one orange tablet daily for 21 consecutive days, fol lowed by 7 days when no tablets are taken.

It is recommended that Aviane -21 tablets be taxen at the same time each day. Sunday start

During the first cycle of medication, the patient is instructed to begin taking AvianeTM -21 on the first Sunday after the onset of menstruation. If menstruation begins on a Sunday, the first lablet (orange) is taken that day. One orange tablet should be taken daily for 21 consecutive days, followed by seven days when no tablet is taken. Withdrawal bleeding should usually occur within three days following discontinuation of orange tablets. During the first cycle, contraceptive reliance should not be placed on Aviane 21 until an orange tablet has been taken daily for 7 consecutive days. The possibility of ovulation and conception prior to initiation of medication should be considered.

The patient begins her next and all subsequent 21-day courses of tablets on the same day of the week (Sunday) on which she began her first course, following the same schedule: 21 days on orange tablets—7 days when no tablets are taken. It in any cycle the patient starts tablets later than the proper day, she should protect herself against pregnancy by using another method of birth control until she has taken an orange tablet daily for 7 consecutive days.

Day 1 start:

During the first cycle of medication, the patient is instructed to begin taking Aviane™ -21 during the first 24 hours of her period (day one of her menstrual cycle). One orange tablet should be taken daily for 21 consecutive days. Withdrawal bleeding should usually occur within three days following discontinuation of orange tablets. If medication is begun on day one of the menstrual cycle, no back-up contraception is necessary. If AvianeTM -21 tablets are started later than day one of the first menstrual cycle or postpartum, contraceptive reliance should not be placed on Aviane™ -21 tablets until after the first 7 consecutive days of administration. The possibility of evulation and conception prior to initiation of medication should be considered.

When the patient is switching from a 21-day regimen of tablets, she should wait 7 days after her last tablet before she starts Aviance. She will probably experience withdrawal bleeding during that week. She should be sure that no more than 7 days pass after her previous 21-day regimen. When the patient is switching from a 28. day regimen of tablets, she should start her first pack of Awane^{na} on the day after her last tablet. She should not wan any days between packs.

It spotting or breakthrough bleeding occur, the patient is instructed to continue on the same regimen. This type of bleeding is usually transient and without signifi-cance; however, if the bleeding is persistent or prolonged, the patient is advised to consult her physician. While there is little likelihood of ovulation occurring if only one or two orange tablets are missed, the possibility of ovulation increases with each successive day that scheduled orange tablets are missed. Although the occur-rence of pregnancy is unlikely if Avianeth is taken according to directions, if withdrawal bleeding does not occur, the possibility of pregnancy must be considered. If the patient has not adhered to the prescribed schedule (missed one or more tablets or started taking them on a day later than she should have), the probability of pregnancy should be considered at the time of the first missed period and appropriate diagnostic measures taken before the medication is resumed. If the patient has adhered to the prescribed regimen and misses two consecutive periods, pregnancy should be ruled out before continuing the contraceptive regimen. The risk of pregnancy increases with each active (orange) tablet missed. For addi-

tional patient instructions regarding missed tablets, see the "WHAT TO DO IF YOU MISS PILLS" section in the **DETAILED PATIENT LABELING** below. In the nonlactating mother, Aviane may be initiated postpartum, for contracep-

tion. When the tablets are administered in the postpartum period, the increased risk of thromboembolic disease associated with the postpartum period must be considered (See 'Contraindications', 'Warnings', and 'Procautions' concerning thromboembolic disease).

How Sepplied

Aviane^m =21 tablets (0.10 mg levonorgestrel and 0.02 mg ethinyl estradiol) are available in cartons of six dispenser cards of 21 tablets each, NDC 51285-015-21. as follows: 21 active tablets, orange, round coated tablet marked "dp" and "016" Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). (See USP rolled room temperature)

References available upon requ

of Sucumery Patient Package Insert

This product (Nite all oral contraceptives) is intended to provent programcy does not protect against MIV infection (AUD3) and other example transmitted & esset.

Oral contraceptives, also known as 'birth-control pills' or 'The pill', are taken to prevent pregnancy, and when taken correctly, have a trailure rate of less than 1,0% per year when used without missing any pills. The typical failure rate of large numbers of pill users is less than 3.0% per year when women who miss pills are included. For most women oral contraceptives are also free of senous or unpleasant side effects. However, forgetting to take pills considerably increases the chances of pregnancy.

For the majority of women, oral contraceptives can be taken safely. But there are some women who are at high risk of developing certain senous diseases that can be life-threatening or may cause temporary or permanent disability or death. The risks associated with taking oral contraceptives increase significantly if you

- smoke.
- · have high brood pressure, diabetes, high cholesterol
- have or have had clotting disorders, heart attack, stroke, angina pectoris, cancer of the breast or sex organs, laundide, or malignant or benign liver tumors

You should not take the pill if you suspect you are pregnant or have unexplained vanishal bleeding.

Ciparette ameking increases the risk of serious adverse effects on the heart and blood vessels from oral contraceptive sto. Talls risk increases with age and with beavy smoking (15 or more ciparettes per day) and is quiting marked in women over 35 years of age. Women who use oral contraceptives should not smoke.

Most side effects of the pill are not senous. The most common such effects are nausea, vomiting, bleeding between menstrual periods, weight gaun, breast tenderness, and difficulty wearing contact lenses. These side effects, especially nausea and vomiting, may subside within the first three months of use.

The senous side effects of the pill occur very infrequently, especially if you are in good health and do not smoke.

However, you should know that the following medical conditions have been associated with or made worse by the pill.

- 1. Blood ctots in the legs (thrombophlebitis), lungs (pulmonary embohsm), stoppage or rupture of a blood vessels in the brain (stroke), blockage of blood vessels in the heart (heart attack and angina pectoris) or other organs of the body. As mentioned above, smoking increases the risk of heart attacks and strokes and subsequences.
- 2. Liver tumors, which may rupture and cause severe bleeding. A possible but not definite association has been found with the pill and liver cancer. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer.
- 3. High blood pressure, although blood pressure usually returns to normal when the pill is stopped

The symptoms associated with these serious side effects are discussed in the detailed leaflet given to you with your supply of pills. Notify your doctor or health-care provider if you notice any unusual physical disturbances while taking the pill in addition, drugs such as rifampin, as well as some anticonvulsants and some antibinities, may decrease pral-contracentive effectiveness.

antibiotics, may decrease oral-contraceptive effectiveness. Studies to date of women taking the pill have not shown an increase in the incidence of cancer of the breast or cervix. There is, however, insufficient evidence to rule out the possibility that pills may cause such cancers. Taking the pill provides some important noncontraceptive benefits. These include less painful menstruation, less menstrual blood loss and anemia, fewer pelvic infections, and fewer cancers of the ovary and the lining of the uterus.

tion, less menstrual blood loss and anemia, tewer pervici intections, and tewer carcers of the ovary and the lining of the uterus.

Be sure to discuss any medical condition you may have with your health-care
provider. Your health-care provider will take a medical and family history before
prescribing oral contraceptives and will examine you. The physical examination
may be delayed to another time if you request it and the health-care provider
believes that it is appropriate to postpone it. You should be reexamined at least
once a year while taking oral contraceptives. The detailed patient information leaflet
gives you further information which you should read and discuss with your healthcare provider.

This product (like all oral contraceptives) is intended to prevent pregnancy, it does not protect against transmission of HIV (AIDS) and other sexually transmitted diseases such as chlamydia, gental herpes, gental warts, gonorrhea, hepatitis B, and synhiis.

DETAILED PATIENT LABELING

This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other saxually transmitted diseases.

INTRODUCTION

Any woman who considers using oral contraceptives (the birth-control pill or the pill) should understand the benefits and risks of using this form of birth control. This leaflet will give you much of the information you will need to make this decision and will also help you determine if you are at risk of developing any of the serious side effects of the pill. It will tell you how to use the pill property so that it will be a settlerible as conscibility.

be as effective as possible. However, this leaflet is not a replacement for a careful discussion between you and your heath-care provider. You should discuss the information provided in this leaflet with him or her, both when you first start taking the pill and during your revists. You should also follow your health-care provider's advice with regard to regular check-ups while you are on the pill.

EFFECTIVENESS OF ORAL CONTRACEPTIVES

Oral contraceptives or "birth-control pills" or "the pill" are used to prevent pregnancy and are more effective than other nonsurgical methods of birth control. When they are taken correctly, the chance of becoming pregnant is less than 1.0% per year when used perfectly, without missing any pills. Typical failure rates are less than 3.0% per year. The chance of becoming pregnant increases with each missed will during the menstrual excele.

In comparison, typical failure rates for other methods of birth control during the first year of use are as follows:

IUD: 3%
Depo-Provera* (injectable progestogen): 0.3%
Norplant* System (implants): 0.1%
Diaphragm with spermicides: 18%
Spermicides alone: 21%
Male condom alone: 12%
Female condom alone: 21%
Cervical cap
Nulliparous women: 18%

Nulliparous women: 18% Parous women: 36% Periodic abstinence: 20% No methods: 85%

WHO SHOULD NOT TAKE ORAL CONTRACEPTIVES

Clearette smoking increases the risk of serious adverse effects on the heart and blood vessels from oral contraceptive see. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quint-sarked in women over 35 years of age. Women who use oral contraceptives should not smake.

regular check-ups while you are on the pill. EFFECTIVENESS OF ORAL CONTRACEPTIVES EFFECTIVENESS OF OMAL CUNTINACEPTIVES
Oral contraceptives or "birth-control pills" or "the pill" are used to prevent pregnancy and are more effective than other nonsumpical methods of birth control. When they are taken correctly, the chance of becoming pregnant is less than 1.0% per year when used perfectly, without missing any pills. Typical failure rates are less than 3.0% per year. The chance of becoming pregnant increases with each missed will during the generical cycle. pill during the menstrual cycle. ar In comparison, typical failure rates for other methods of birth control during the first year of use are as follows: IUD: 3% Depo-Provera* (injectable progestogen): 0.3% Norplant* System (implants): 0.1% Diabhragm with spermicides: 16% Spermicides alone: 21% Male condom alone: 12% Female condom alone: 21% 30 21 19 Parous women: 36% Periodic abstinence: 20% No methods: 85% WHO SHOULD NOT TAKE ORAL CONTRACEPTIVES Cigaretre smoking increases the risk of serious neverse effects on the heart and blood vessels from eral contraceptive use. This risk increases with are and blood vessels from eral contraceptive use. This risk increases with an end with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of ege. Women who use oral contraceptives should not smokin. ect smoke. Some women should not use the pill. For example, you should not take the pill if you are pregnant or think you may be pregnant. You should also not use the pill if you have had any of the following conditions: o by of the aya · Heart attack or stroke. Blood clots in the legs (thrombophlebitis), lungs (pulmonary embotism), or eyes. Blood clots in the deep veins of your legs. . Known or suspected breast cancer or cancer of the liming of the uterus, cervix or v20102. · Liver tumor (benign or cancerous). Or, it you have any of the following: • Chest pain (angina pectoris). Unexplained vaginal bleeding (until a diagnosis is reached by your doctor). Yellowing of the whites of the eyes or of the skin (jaundice) during pregnancy or during previous use of the pill. Tell your health-care provider if you have ever had any of these conditions. Your health-care provider can recommend another method of birth control. OTHER CONSIDERATIONS BEFORE TAKING ORAL CONTRACEPTIVES Tell your health-care provider if you or any tamily member has ever had Breast nodules, hiprocystic disease of the breast, an abnormal breast X ray or mammogram. Diabetes. Elevated cholesterol or triglycerides. High blood pressure. Migraine or other headaches or epilepsy. ntal depression · Gallbladder, heart or kidney disease History of scanty or irregular menstrual periods. Women with any of these conditions should be checked often by their health-care women wan any or mese conditions should be enecised offer by their nearth-care provider it they choose to use oral contraceptives. Also, be sure to inform your doctor or health-care provider if you smoke or are on any medications RISKS OF TAKING ORAL CONTRACEPTIVES

1. Risk of developing blood clots Blood clots and blockage of blood vessels are the most serious side effects of taking oral contraceptives and can be fatal. In particular, a clot in the legs can cause thrombophiebitis and a clot that travels to the lungs can cause a sudden blocking of the vessel carrying blood to the lungs. Rarely, clots occur in the blood vessels of the eye and may cause blindness, double vision, or impaired vision If you take oral contraceptives and need elective surgery, need to stay in bed for a prolonged illness, or have recently delivered a baby, you may be at risk of developing blood clots. You should consult your doctor about stopping oral contracepoping blood clots. You should consult your doctor about stopping oral contraceptives three to four weeks before surgery and not taking oral contraceptives shall be surgery or during bed rest. You should also not take oral contraceptives soon after delivery of a baby or a midtimmester pregnancy termination. It is advisable to wait for at least four weeks after delivery if you are not breast-leeding, you should wait until you have weared your child before using the pill. (See also the section on breast-leeding in "GENERAL PRECAUTIONS.") 2 Heart attacks and strokes Oral contraceptives may increase the tendency to develop strokes (stoppage or rupture of blood vessels in the brain) and angina pectons and heart attacks (blockage of blood vessels in the heart). Any of these conditions can cause death or sen-Smoking greatly increases the possibility of suffering heart attacks and strokes. Furthermore, smoking and the use of oral contraceptives greatly increase the chances of developing and dying of heart disease. 3 Gallbladder disease Oral-contraceptive users probably have a greater risk than nonusers of having gallbladder disease, although this risk may be related to pills containing high doses of estrogens In rare cases, oral contraceptives can cause benign but dangerous liver tumors. These benign liver tumors can rupture and cause tatal internal bleeding, in addition, a possible but not definite association has been found with the pill and liver non, a possible our not definite association has been found with the pin and lifet cancers in two studies in which a few women who developed these very rare cancers were found to have used oral contraceptives for long periods. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer. 5. Cancer of the reproductive organs

You should also follow your health-care provider's ad

who use oral contraceptives and have a strong family history of breast cancer or who have breast nodules or abnormal mammograms should be closely followed by their doctors. Some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. However, this finding may be related to fac-tors other than the use of oral contraceptives.

There is, at present, no confirmed evidence that oral contraceptives increase the nsk of cancer of the reproductive organs in human studies. Several studies have found no overall increase in the risk of developing breast cancer. However, women

ESTIMATED RISK OF DEATH FROM A BIRTH-CONTROL METHOD OR PREGNANCY All methods of birth control and pregnancy are associated with a risk of developing certain diseases which may lead to disability or death. An estimate of the number of deaths associated with different methods of birth control and pregnancy has been calculated and is shown in the following table.

ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCI-ATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN, BY

Method of control and outcome	15-19	20-24	25-29	30-34	35-39	40-44
No fertility-control methods*	7.0	7.4	9.1	14.8	25.7	28.2
Oral contraceptives nonsmoker**	0.3	0.5	0.9	1.9	13.8	31.6
Oral contraceptives smoker**	2.2	.3 4	6.6	13.5	51.1	117.2
IND	0.8	08	1.0	1.0	14	1.4
Condom*	11	1.6	0.7	0.2	0.3	04
Diaphragm/spermicide*	1.9	1.2	1.2	1.3	2.2	28
Periodic abstinence	2.5	1.6	1.6	1.7	2.9	3.6

- · Deaths are birth-related
- Deaths are method-related

In the above table, the risk of death from any birth-control method is less than the In the above table, the risk of death from any birth-control melods season which is do childyone, except for 'oral-contraceptive users over the age of 35 who smoke and pill users over the age of 40 even if they do not smoke. It can be seen in the table that for women aged 5 to 39, the risk of death was highest with pregnancy. (7 to 26 deaths per 100.000 women, depending on age). Among pill users who do not smoke, the risk of death was always lower than that associated with pregnanciates are considered for these areas over the age of 40, when the risk cy for any age group, except for those women over the age of 40, when the risk increases to 32 deaths per 100,000 women, compared to 28 associated with pregnancy at that age. However, for pill users who smoke and are over the age of 35. the estimated number of deaths exceeds those for other methods of birth control If a woman is over the age of 40 and smokes, her estimated risk of death is four times higher (117/100.000 women) man the estimated risk associated with pregnancy (28/100.000 women) in that age group.

The suggestion that women over 40 who don't smoke should not take oral contrathe suggestion has written over a wind out in high-dose pills and on less-selective use of pills than is practiced today. An Advisory Committee of the FDA discussed this issue in 1989 and recommended that the benefits of oral-contraceptive use by healthy, nonsmoking women over 40 years of age may outweigh the possible risks However, all women, especially older women, are cautioned to use the lowest-dose pill that is effective.

WARNING SIGNALS

- If any of these adverse effects occur while you are taking oral contraceptives, call
- your doctor immediately.

 Sharp chest pain, coughing of blood, or sudden shortness of breath (indicating a
- possible clot in the lung).

 Pain in the calf (indicating a possible clot in the leg).

 Crushing chest pain or heaviness in the chest (indicating a possible heart attack).
- Sudden severe headache or vomiting, dizziness or fainting, disturbances of vision or speech, weakness, or numbness in an arm or leg (indicating a possible stroke).
- Sudden partial or complete loss of vision (indicating a possible clot in the eye).
 Breast lumps (indicating possible breast cancer or fibrocystic disease of the
- breast; ask your doctor or healthcare provider to show you how to examine your breasts).
- · Severe pain or tenderness in the stomach area (indicating a possibly ruptured liver tumor).
- Difficulty in steeping, weakness, tack of energy, fatigue, or change in mood (possibly indicating severe depression).
- Jaundice or a yellowing of the skin or eyeballs, accompanied frequently by lever, fatigue, loss of appetite, dark-colored urme, or light-colored bowel movements (indicating possible liver problems).

SIDE EFFECTS OF ORAL CONTRACEPTIVES

Irregular vaginal bleeding or spotting may occur while you are taking the pills. Irregular bleeding may vary from slight staining between menstrual periods to breakthrough bleeding which is a flow much like a regular period.

irregular bleeding occurs most often during the first few months of oral-contra-ceptive use, but may also occur after you have been taking the pill for some time. Such bleeding may be temporary and usually does not indicate any serious prob-lems. It is important to continue taking your pilts on schedule. If the bleeding occurs in more than one cycle or tasts for more than a few days, talk to your doctor or health-care provider.

2 Contact lenses

If you wear contact lenses and notice a change in vision or an inability to wear your lenses, contact your doctor or health-care provider

3. Fluid retention

Oral contraceptives may cause edema (fluid retention) with swelling of the fingers or ankles and may raise your blood pressure. If you experience fluid retention, contact your doctor or health-care provider.

4. Melasma

A spotty darkening of the skin is possible, particularly of the face.

5. Other side effects

Other side effects may include change in appetite, headache, nervousness, depres sion, dizziness, loss of scalp hair, rash, and vaginal infections.

If any of these side effects bother you, call your doctor or health-care provider. GENERAL PRECAUTIONS

Missed periods and use of oral contraceptives before or during early pregnancy.

There may be times when you may not menstruate regularly after you have completed taking a cycle of pills. If you have taken your pills regularly and miss one menstrual period, continue taking your pills for the next cycle but be sure to inform your health-care provider before doing so. If you have not taken the pills daily as instructed and missed a menstrual period, or if you missed two consecutive menstrual periods, you may be pregnant. Check with your health-care provider imme-diately to determine whether you are pregnant. Do not continue to take oral contraceptives until you are sure you are not pregnant, but continue to use another method of contraception

There is no conclusive evidence that oral-contraceptive use is associated with an increase in birth detects, when taken inadvertently during early pregnancy.

Previously, a few studies had reported that oral contraceptives might be associatriewidsty, a rew studies had reported in our confirmed. Nevertheless, or all contraceptives or any other drugs should not be used during pregnancy unless clearly necessary and prescribed by your doctor. You should check with your doctor about risks to your unborn child of any medication taken during pregnancy.

If you are breast-feeding, consult your doctor before starting oral contraceptives. Some of the drug will be passed on to the child in the milk. A few adverse effects on the child have been reported, including yellowing of the skin (jaundice) and breast enlargement, in addition, oral contraceptives may decrease the amount and quality of your milk. It possible, do not use oral contraceptives white breast-feeding. You should use another method of contraception since breast-feeding provides only partial protection from becoming preparal and this partial protection decreases significantly as you breast-feed for longer periods of time. You should consider starting oral contraceptives only after you have wearied your child com-

pletely.

If any of these side effects bother you, call your doctor or health-care provider GENERAL PRECAUTIONS Missed periods and use of oral contraceptives before or during early preg Messou persons and use or or all contractions are the contract or owner any properties. If there may be times when you may not menstruate regularly after you have completed taking a cycle of pills. If you have taken your pills regularly and miss one

menstrual period, continue taking your pills for the next cycle but be sure to intom your health-care provider before doing so. If you have not taken the pills daily as instructed and missed a menstrual period, or if you missed two consecutive menstrual periods, you may be pregnant. Check with your health-care provider immeduately to determine whether you are pregnant. Do not continue to take oral contraceptives until you are sure you are not pregnant, but commue to use another method of contraception.

There is no conclusive evidence that oral-contraceptive use is associated with an increase in birth detects, when taken inadvertently during early pregnancy. Previously, a few studies had reported that oral contracentives might be associated with birth defects, but these studies have not been confirmed. Nevertheless, oral contraceptives or any other drugs should not be used during pregnancy unless clearly necessary and prescribed by your doctor. You should check with your doctor. tor about risks to your unborn child of any medication taken during pregnancy.

2. While breast-feeding

2. Write preast-reeding.
If you are breast-reeding, consult your doctor before starting oral contraceptives.
Some of the drug will be passed on to the child in the milk. A tew adverse effects on the child have been reported, including yellowing of the skin (paundice) and breast enlargement. In addition, oral contraceptives may decrease the amount and quality of your milk. If possible, do not use oral contraceptives while breast-leeding, you should use another method of contraception since breast-leeding. You should use another method of contraception since breast-leeding provides only partial protection from becoming pregnant and this partial protection decreases significantly as you breast-feed for longer periods of time. You should consider starting oral contraceptives only after you have weared your child com-

3. Laboratory tests

If you are scheduled for any laboratory tests, tell your doctor you are taking birthcontrol pilts. Certain blood tests may be affected by birth-control pills.

4. Drug interactions Certain drugs may interact with birth-control pills to make them less effective in certain usings may messes an increase in breakthrough bleeding. Such drugs preventing pregnancy or cause an increase in breakthrough bleeding. Such drugs preventing trampin, drugs used for epitepsy such as barbiturates (for example, phenobarbital) and phemytoin (Dilantin is one brand of this drug), phenyibutazone (Butazolidin is one brand) and possibly certain antibiotics. You may need to use an additional method of contraception during any cycle in which you take drugs that can make oral contraceptives less effective.

This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted diseases such as chiamydia, genital herpes, genital warts, gonormea, hepatitis B, and syphilis

HOW TO TAKE THE PILL

This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmi eases such as chiamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis

IMPORTANT POINTS TO REMEMBER
BEFORE YOU START TAKING YOUR PILLS: 1. BE SURE TO READ THESE DIRECTIONS.

Before you start taking your pills. And

Anytime you are not sure what to do.

2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME.

If you miss pills you could get pregnant. This includes starting the pack tate. The more pills you miss the more likely you are to get pregnant.

3. MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO

THEIR STOMACH DURING THE FIRST 1-3 PACKS OF PILLS.

If you feel sick to your stomach, do not stop taking the pill. The problem will usually go away, If it doesn't go away, check with your doctor or clinic.

4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT BLEEDING, even when

4. MISSING PILLS CAN ALSO CAUSE SPOTTING ON LIGHT BLEEDING, even when you make up these missed pills. On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach.
5. IF YOU HAVE VOMITING OR DIARRHEA, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your pills you to work as well. Use a back-up method (such as condoms or toam) until you check with your doc-

6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill-taking easier or about using another method of

7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic.

BEFORE YOU START TAKING YOUR PILLS

1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the same time every day.


2. LOOK AT YOUR PILL PACK TO SEE IF IT HAS 21 OR 28 PILLS:

The 21-pill pack has 21 'active' orange pilts (with hormones) to take for 3 weeks, followed by 1 week without pills.

The 28-pill pack has 21 'active' orange pills (with hormones) to take for 3 weeks, followed by 1 week of 'reminder' light-green pills (without hormones).

3. ALSO FIND:

1) where on the pack to start taking pills,
2) in what order to take the pills (follow the arrows) and
3) the week numbers as shown in the following example.




: BE SURE YOU HAVE READY AT ALL TIMES: WOTHER KIND OF BIRTH CONTROL (such as condoms or toam) to use as a backip method in case you miss pills. IN EXTRA, FULL PILL PACK.

THEN TO START THE FIRST PACK OF PILLS:

ou have a choice of which day to start taking your first pack of pills. Decide with our doctor or clinic which is the best day for you. Pick a time of day which will be asy to remember.

Pick the day label strip that starts with the first day of your period (this is the day you start bleeding or spottung, even if it is almost midnight when the bleeding begins).

Place this day label strip on the cycle tablet dispenser over the area that has the days of the week (starting with Sunday) printed on the dispensing Card days of the week (starting with Sunday).



Note: If the first day of your period is a Sunday, you can skip steps #1 and #2.

Take the first 'active' [prange-colored] pill of the first pack during the hiss 24.

Take the first 'active' [prange-colored] pill of the first pack during the hiss 24.

Note: If the first day of your period is a Sunday, you can skip steps #1 and #2.

3. Take the first "active" [orange-colored] pill of the first pack during the hirst 24.

A You win not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period.

Sunday START

1. Take the first "active" [orange-colored] pill of the first pack on the Sunday after your period starts, even if you are still bleeding. If your period begins on your period starts, even if you are still bleeding. If your period begins on Sunday, start the pack that same day.

2. Use another method of birth control as a back-up method if you have sex any. Condoms or toam are good back-up methods of birth control.

Condoms or toam are good back-up methods of birth control.

1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY.

Do not skip pills even if you are sporting or bleeding between monthly periods or leet sick to yoll seven if you do not have sex very often.

2. WHEN YOU FINISM A PACK OR SWITCH YOUR BRAND OF PILLS.

2. THE WAIT OF AGYS to Start the next pack, You will probably have your long that week. Be sure that no more train 7 days pass between 21-day packs.

WHAY TO DO IF YOU MISS PILLS

WHAY TO DO IF YOU MISS PILLS

WHAY TO DO IF YOU MISS PILLS

WHAY TO DO IF YOU MISS PILLS ing that week. Be sure that no more than 7 days pass between 21-day packs. 28 pills: Start the next pack on the day after your last "reminder" pill. Do not wait any days by the pill to not wait any days for any days pack of the pill to not wait any days for any a schee pill.

I you MISS 1 orange "active" pill:

1. Take it as soon as you remember. Take the next pill at your regular time. This means you take 2 pills in 1 day.

2. You do not need to use a back-up birth-control method if you have sex.

1. You MISS 2 orange "active" pills in a row in WEEK 9 OR WEEK 2 of your pack:

1. Take 2 pills on the day you remember and 2 pills the next day.

2. Then take 1 pill a day until you finish the pack.

3. You MISS 2 orange "active" pills in a row in the 7 days after you miss pills.

3. You MISS active Perconant if you have sex in the 7 days after you miss pills.

3. You MISS 2 orange "active" pills in a row in THE 3rd WEEK.

1. If you are a Day 1 Starter.

1. If you are a Senday Starter.

1. If you may be a senday Starter.

1. If you may be a senday Starter.

1. If you may not have your period this month but this is evenerated. Moseure it unit.

same day.

2. You may not have your period this month but this is expected. However, if you may not have your period 2 months in a row, call your doctor or clinic because you might miss your period 2 months in a row, call your doctor or clinic because you might miss your period.

miss your period 2 months in a row, call your doctor of climic because you miss police to pregnant. 3. You MAY BECOME PREGNANT if you have sex in the 7 days after you miss pills 3. You MAY BECOME PREGNANT if you have sex in the 7 days after you miss pills a back-up for those 7 days. If you MISS 3 OR MORE orange "active" pills in a row (during the first 3 weeks): 1. Wyww are a Day 1 Starter. THROW OUT the rest of the pill pack and start a new pack that same day. Wyw are a Standay Starter. Keep taking 1 pill every day until Sunday. On Sunday. THROW OUT the rest of the pack and start a new pack of pills that same day. THROW OUT the rest of the pack and start a new pack of pills that same day.

same day.

2. You may not have your period this month but this is expected. However, it you may not have your period 2 months in a row, call your doctor or clinic because you might miss your period 2 months in a row.

miss your period 2 months in a row, call your doctor or clinic because you might be pregnant.

3. You MAY BECOME PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth-control method (such as condoms or foam) as a back-up for those 7 days.

A REMINDER FOR THOSE ON 28-DAY PACKS:
If you forget any of the 7 light-green 'reminder' pills in Week 4:
THROW AWAY the pills you missed.
Keep taking 1 pill each day until the pack is empty.
You do not need a back-up method it you start your next pack on time.

FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU

FIRALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU NATE WISSED

KEEP TAKING ONE PILL EACH DAY until you can reach your doctor or clinic.

KEEP TAKING ONE PILL EACH DAY until you can reach your doctor or clinic.

The incidence of pill tailure resulting in pregnancy is approximately less than 1.0% if taken every day as directed, but more typical failure rates are less than 3.0%. If allure does occur, the risk to the tetus is minimal.

RISKS TO THE FETUS

If you do become pregnant while using oral contraceptives, the risk to the tetus is 3.0% in the order of no more than one per thousand. You should, however, discuss the risks to the developing child with your doctor.

Pregnancy after stopping the pill

There may be some delay in becoming pregnant after you stop using oral contraceptives, especially if you had irregular menstrual cycles before you used oral contraceptives. In may be advisable to postophe conception until you begin menstruating the pill and desire pregnancy, attent goularly once you have stopped taking the pill and desire pregnancy. There does not appear to be any increase in birth detects in newborn babies when pregnancy occurs soon after stopping the pill

Overdosage

Serious ill effects have not been reported following ingestion of large doses of oral contractives. It makes, in case of overdosage, contact your health-care provider of pharmacist.

Other information

bleeding in termans.


Instruction

Other information

Your health-care provider will take a medical and tamity history before prescribing

Other information

Your health-care provider will take a medical and tamity history before shall be a calconitracephives and will examine you. The physical examination may be delayed oral contracephives and will examine you. The physical examination may be delayed for all conditions on a contract the provider of the rees as tamity history of any of the conditions of the provider if there is a family history of any of the conditions your health-care provider if there is a family history of any of the conditions histed previously in this leaflet. Be sure to keep all appointments with your transfer of the previously in this leaflet. Be sure to keep all appointments with your transfer of the previously in this leaflet. Be sure to keep all appointments with your transfer of the previously in this leaflet. Be sure to keep all appointments with your transfer of the previously in this leaflet. Be sure to keep all appointments with your transfer of the previously in this leaflet. Be sure to keep all appointments with your transfer of the previously in this leaflet. Be sure to keep all appointments with your transfer of the previously in this leaflet. Be sure to keep all appointments with your transfer of the previously in this leaflet.



(levonorgestrel and ethinyl estradiol)

Patients should be counseled that this product does not proteg infection (AIDS) and other sexually transmitted diseases.

B only

Description

21 orange active tablets each containing 0.10 mg of levonorgestrel. d(-1-13):
ethiyl-17c-ethinyl-17B-hydroxygon-4-en-3-one, a totally synthetic progestogen, and 0.02 mg of ethinyl estratiol. 17c-ethinyl-1.35(10)-estratrene3.17p-doil. The inactive ingredients present are: FD&C Yellow No. 6 Aluminum
Lake, hydroxypropyl methylcetilulose, lactose monohydrate, magnesium
stearale, microcrystalline cellulose, polyethylene glycol, pregelatinized starch,
2 Light-green, ment tablets dattanium dioxide.
2 Light-green, ment tablets dattanium dioxide.
3 Blue No. 1 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake, Letose monohydrate, magnesium stearate, microcrystalline cellulose and pregelatinized starch.

MW: 312.45

MF: C21H28O2

Ethinyl Estradiol

MF: C₂₀H₂₄O₂

Clinical Pharmacology
Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry tion).

PHARMACOKINETICS

Attentions

tion).


PHARMACOKINETICS

Absorption

No specific investigation of the absolute bioavailability of Aviane™ (levonorgestrel and ethinyl estradiol) tablets in humans has been conducted. However, literature and ethinyl estradiol) tablets in humans has been conducted. However, literature indicator that tevonorgestrel is rapidly and competely absorbed after oral administration that the properties of the prope

FIGURE 1

Mean (SE) levonorgestrel and ethinyl estradiol serum concentrations in 22 subjects receiving 100 µg levonorgestrel and 20 µg ethinyl estradiol



			Livonorgestre	#		
Day		T _{restex}	AUC no-h/mL	CL/F mL/hAz	VX2F L/Ka	SHBG
1	275 (0.88)	1.6 (0.9)	35.2 (12.8)	53.7 (20.6)		nmol/L
6	4.52 (1.79)	15 (0.7)			2.66 (1.09)	57 (18)
21	600 (2.65)		46.0 (18.8)	40.8 (14.5)	2.05 (0.86)	81 (25)
	0.00 (2.00)	1.5 (0.5)	68.3 (32.5)	28.4 /10.31	1.42 (0.00)	~~

_	pom.	<u> </u>	pg-fr/mL	L/h/kg	Uko	fu %
6	51.2 (12.9) 77.9 (22.0)	1.5 (0.7)	654 (201) 794 (240)	279 (0.97)	135.9 (41.B) 1.9	2 (0.30)
21	103.6 (36.9)	1.5 (0.5)	1177 (462)	1.57 (0.49)	78.6 (29.7) 1.8	

	pg/mi_	h	po-tvmL	mLANG	LAcc	
1	62.0 (20.5)	1.5 (0.5)	663 (227)			
6	76.7 (29.9)			567 (204)	14.3 (37)	
21		1.3 (0.7)	604 (231)	610 (196)	15.5 (4.0)	
	82.3 (33.2)	1.4 (0.6)	776 (308)	496 (170)	124444	

		Levonorgestre	4		
C _{max}	T _{max}	AUC ngrivini,	CL/F mL/hAsp	Vλ±F LÆG	SHBG mmal/L
2.75 (0.88)	1.6 (0.9)	35.2 (12.6)	53.7 (20.8)		57 (18)
4.52 (1.79)	15 (0.7)				81 (25)
6.00 (2.65)	15 (0.5)	68.3 (32.5)	28.4 (10.3)	1.43 (0.62)	93 (40)
	10/mL 2.75 (0.88) 4.52 (1.79)	C _{max} T _{max} ng/mL h 2.75 (0.88) 1.6 (0.9) 4.52 (1.79) 1.5 (0.7)	C _{max} T _{max} AUC ng/mi. h ng/mint. 2/75 (0.88) 1,6 (0.9) 35.2 (12.8) 4.52 (1.79) 15 (0.7) 46.0 (18.8)	10/ml. h ng/h/ml. ml/h/ng 2.75 (0.88) 1.6 (0.9) 35.2 (12.6) 53.7 (20.8) 4.52 (1.79) 1.5 (0.7) 46.0 (18.6) 40.8 (14.5)	C _{max} rg/ml. T _{max} h AUC rg/ml. CLF mL/May VADF L/kg 275 (0.88) 1.6 (0.9) 35.2 (12.8) 53.7 (20.8) 2.66 (1.09) 4.52 (1.79) 1.5 (0.7) 48.0 (18.8) 40.8 (14.5) 2.05 (0.86)

1	51.2 (12.9)	1.5 (0.9)	664 (201)	279 (0.97)	135.9 (41.8)	1.92 (0.30)
6	77.9 (22.0)	1.5 (0.7)	794 (240)	2.24 (0.59)	112.4 (40.5)	
21	103.6 (36.9)	1.5 (0.5)	1177 (452)	1.57 (0.49)	78.6 (29.7)	
		-	Etheryl Estradiol			
_	pg/ml	h	powers	mL/Mg	LANG	
7	62.0 (20.5)	1.5 (0.5)	653 (227)	567 (204)	143 (37)	
6	76.7 (29.9)	1.3 (0.7)	604 (231)	610 (196)	15.5 (4.0)	
21	82.3 (33.2)	1.4 (0.5)	776 (308)	486 (179)	124 (41)	

Distribution

Metabolism

Induces once synthesis.

Levonorpestret: The most important metabolic pathway occurs in the reduction of the A4-3-oxo group and hydroxylation at positions 2o. 18, and 168, followed by conjugation. Most of the metabolites that circulate in the blood are surfates of 3a.55-fetralydro-levonorpestret, while excretion occurs predominantly in the form of glucuronides. Some of the parent levonorpestret also circulates as 178-suitate. Metabolic Clearance rates may differ among individuals by severation(), and this may account in part for the wide variation observed in levonorpestret concentrations among users.

Ethinyl estradiol, Cytochrome P450 enzymes (CYP3A4) in the liver are responsible both to 2-hydroxylation that is the major oxidative reaction. The 2-hydroxylation that is the major oxidative reaction. The 2-hydroxylation that is the major oxidative reaction. The 2-hydroxylation and glucuronidation prior to urritary and fecal exerction. Levels or mitigation and glucuronidation prior to urritary and fecal exerction. Levels or mitigation are solid their very series of chipylation. Ethinyl estradiol is excreted in the urine and feces as glucuronida and suitate conjugates, and undergoes enteroheat circulation.

Excretion

The elimination half-life for levonorgestrel is approximately 36 ± 13 hours at steady state.

State. Levonorpestrel and its metabolites are primarily excreted in the unine (40% to 68%) and about 16% to 48% are excreted in feces. The elimination half-life of ethiny estration is 18 ± 4.7 hours at steady state.

SPECIAL POPULATIONS

Based on the pharmacokinetic study with levonorgestrel and ethinyl estradiol 0.10 mg/0.02 mg tablets, there are no apparent differences in pharmacokinetic parameters among women of different races.

mepatic insumiciency.

No formal studies have evaluated the effect of hepatic disease on the disposition of Awaneth (levonorgestrel and ethinyl estradiol) tablets. However, steroid hormones may be poorly metabolized in patients with impaired lever function.

No formal studies have evaluated the effect of renal disease on the disposition of

No formal studies have evaluated the effect of renal disease on the disposition of Avaneth. No formal studies have evaluated the effect of renal disease on the disposition of Avaneth. Drug-Drug Interactions
Interactions between ethinyl estradiol and other drugs have been reported in the interature.

Interactions with Absorption: Diarrhea may increase gastrointestinal motility and reduce hormone absorption. Similarly, any drug which reduces gut transit time may reduce hormone concentrations in the blood.

Interactions with Metabolism:
Gastrointestinal walf: Sulfation of ethinyl estradiol has been shown to occur in the pastrointestinal walf: Sulfation of ethinyl estradiol has been shown to occur in the pastrointestinal walf: Sulfation of ethinyl estradiol hosevaliability (e.g., ascorbic acid). If wall may increase ethinyl estradiol bioavailability (e.g., ascorbic acid). If wall may increase ethinyl estradiol bioavailability (e.g., ascorbic acid). If wall may increase ethinyl estradiol concentrations (e.g., interference with Enterohepatic Circulation: Some clinical reports suggest that enterohepatic circulation of estrogens may decrease when certain antibotic agriculture of the Metabolism of Other Drugs: Ethinyl estradiol oncentrations (e.g., ampliculin, tetracycline).

Interference in the Metabolism of Other Drugs: Ethinyl estradiol may interfere with the metabolism of other drugs by inhibiting hepatic microsomal enzymes with the metabolism of other drugs by inhibiting hepatic microsomal enzymes of corrections and base of the process of the p

TABLE II: PERCENTAGE OF WOMEN EXPERIENCING AN UNINTENDED PREGNANCY DURING THE FIRST YEAR OF USE OF A CONTRACEPTIVE METHOD

Method	Perfect Use	Typical Use	
Norplant ^e System (6 capsules)	0.1	0.1	
Male sterilization	0.1	0.15	
Female sterilization	0.4	0.4	
Depo-Provera* (injectable progest	logen) 0.3	0.3	
Oral contraceptives		3	
Combined	0.1	NA	
Progestin only	0.5	NA	
IUD		74.5	
Progesterone	1.5	2.0	
Copper T 380A	0.6	0.8	
Condom (male) without spermicid		12	
(female) without spermicide	5	21	
Cervical cap	•	21	
Nulliparous women	9	18	
Parous women	26	36	
Diaphragm with spermicidal		36	
cream or jelly	6	18	
Spermicides alone	v	10	
(foam, creams, jellies, and va	ninal		
Suppositories)	y	21	
Periodic abstinence (all methods)	1-9*	20	
Withdrawal	4	19	
No contraception (planned pregnat	ncy) 85	85	

^{*}Depending on method (calendar, ovulation, symptothermal, post-ovulation) Adapted from Hatcher RA et al., Contraceptive Technology, 16th Revised Edition. New York, NY: Irvington Publishers, 1994.



100400(

ablets) against HIV Mfd. by: DURAMED PHA CINCINNATI, OH

100400

30

in a clinical trial with levonorgestrel and ethinyl estradiol 0.10 mg/0.02 mg tablets 1.477 subjects had 7.720 cycles of use and a total of 5 pregnancies were reported. 1.477 subjects had 7.720 cycles of use and a total of 5 pregnancies were reported. This represents an overall pregnancy rate of 0.84 per 100 woman-years. This rate includes patients who did not take the drug correctly. One or more pills were missed during 1.479 (18.8%) of the 7.870 cycles; thus all tablets were taken during 5.391 (81.2%) of the 7.870 cycles. Of the total 7.870 cycles, a total of 150 cycles were excluded from the calculation of the Pearl index due to the use of back-up contraception and/or missing 3 or more consecutive pills.

Contrainelizations
Oral contraceptives should not be used in women with any of the following conditions:
Thrombophilebitis or thromboembolic disorders
A past history of deep-vein thrombophilebitis or thromboembolic disorders
Cerebrovascular or coronary artery disease
Known or suspected carcinoma of the breast
Carrinoma of the endometrium or other known or suspected estronen-denendent

Carcinoma of the endometrium or other known or suspected estrogen-dep

Undiagnosed abnormal genital bleeding

unuajuruscu auruminei vermai viecumiy Cholestatic jaundice of pregnancy or jaundice with prior pill use Hepanic adenomas or carcinomas

Warnings

Cigarette smoking increases the risk of serious cardiovascular side offocis from oral-contraceptive ses. This risk increases with see and with leavy smeking (15 or more cigarettes per day) and is quite marked in on over 35 years of age. Women who are oral centraceptives at be strengly advised not to an

The use of oral contraceptives is associated with increased risks of several senious conditions including myocardial infarction, thromboemboilsm, stroke, hepatic neo-plassa, galiblader disease, and hypertension, atthough the risk of senious morbiolity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, obesity and diabetes.

Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks.

minimation retaining to mose risks.

The information contained in this package insert is principally based on studies carried out in patients who used oral contraceptives with higher formulations of estrogens and progestogens than those in common use today. The effect of tongeries are the oral contraceptives with lower doses of both estrogens and progestogens remains to be determined.


progestogens remains to be determined.

Throughout this tabeling, epidermological studies reported are of two types: retrospective or case control studies and prospective or cohort studies. Case control
studies provide a measure of the relative risk of disease, namely, a ratio of the incidence of a disease among oral-contraceptive users to that among nonusers. The
relative risk does not provide information on the actual clinical occurrence of a disease. Cohort studies provide a measure of attributable risk, which is the difference
in the incidence of disease between oral-contraceptive users and nonusers. The
attributable risk does provide information about the actual occurrence of a disease
in the population. For further information, the reader is referred to a text on epidemological methods.

1. THROMBOEMBOLIC DISORDERS AND OTHER VASCULAR PROBLEMS a. Myocardial Infarction

An increased risk of myocardial infarction has been attributed to oral-contraceptive An increased risk of myocardial infarction has been attributed to oral-contraceptive use. This risk is primarily in smokers or women with other underlying risk factors for coronary-arrey disease such as hypertension, hypercholesterolemia, morbid obesity, and diabetes. The relative risk of heart attack for current oral-contraceptive users has been estimated to be two to six. The risk is very low under the age of 30. users has been estimated to be two to six. The risk is very low under the age of 30. Smoking in combination with oral-contraceptive use has been shown to contribute substantially to the incidence of impocardial infarction in women in their mid-thirties or oder with smoking accounting for the majority of excess cases. Mortality rates associated with circulatory disease have been shown to increase substantial-among women who use oral contraceptives.

CIRCULATORY DISEASE MORTALITY RATES PER 100,000 WOMAN YEARS BY AGE, SMOKING STATUS AND ORAL-CONTRACEPTIVE USE



Oral contraceptives may compound the effects of well-known risk factors, such as hypertension, diabetes, hyperlipidemias, age and obesity. In particular, some progestogens are known to decrease HDL cholesterol and cause glucose intolerance, while estrogens may create a state of hypermsulinism. Oral contraceptives have been shown to increase blood pressure among users (see section 9 m Warm Similar effects on risk factors have been associated

among women who use only contraceptive

CIRCULATORY DISEASE MONTALITY RATES PER 100,000 WOMAN YEARS BY AGE, SMOKING STATUS AND ORAL-CONTRACEPTIVE USE




TABLE III. (Adapted from P.M. Layde and V. Beral, Lancet, 7:541-546, 1981.)

Oral contraceptives may com pound the effects of well known risk factors, such as hypertension, diabetes, hyperlipidemias, age and obesity. In particular, some progestogens are known to decrease HDL cholesterol and cause glucose intolerance, while estrogens may create a state of hypennsulmism. Oral contraceptives have been shown to increase blood pressure among users (see section 9 in "Warnings"). Similar effects on risk factors have been associated with an increased risk of heart disease. Oral contraceptives must be used with caution in women with cardiovascular disease risk factors.

b. Thromboembolism An increased risk of throm-

boembolic and thrombotic disease associated with the use of oral confraceptives is well-established: Case control studies have found the rela-

tive risk of users compared to non-users to be 3 for the first episode of superficial venous thrombosis. 4 to 11 for deep-vein thrombosis or pulmonary embolism, and 1.5 to 6 for women with predisposing conditions for venous thromboembolic disease. Cohort studies have shown the relative risk to be somewhat lower, about 3 for new cases and about 4.5 for new cases requiring hospitalization. The risk of thromboembolic disease due to oral comtraceptives is not related to length of use and disappears after pill use is stopped.

A two- to four-fold increase in relative risk of postoperative thromboembolic complications has been reported with the use of oral contraceptives. The relative risk of venous thrombosis in women who have predisposing conditions is twice that of women without such medical conditions. It feasible, oral contraceptives should be discontinued at least four weeks prior to and for two weeks after elective surgery of a type associated with an increase in risk of thromboembolism and duning and following prolonged immobilization. Since the immediate post-partum period is also associated with an increased risk of thromboembolism, oral contraceptives should be started no earlier than four to six weeks after delivery in women who elect not to breast-feed, or a midtrimester pregnancy termination.

c. Cerebrovascular diseases

Oral contraceptives have been shown to increase both the relative and attributable risks of cerebrovascular events (Hrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (-035 years), hypertensive women who also smoke. Hypertension was found to be a risk factor for both users and nonusers, for both types of strokes, while smoking interacted to increase the risk for hemorrhagic strokes.

In a large study, the relative risk of thrombotic strokes has been shown to range from 3 for normotensive users to 14 for users with severe hypertension. The relative risk of hemorrhagic stroke is reported to be 1.2 for nonsmokers who used oral contraceptives, 2.6 for smokers who did not use oral contraceptives, 7.6 for smokers who used oral contraceptives, 1.8 for normotensive users and 25.7 for users with severe hypertension. The attributable risk is also greater in older women.

d. Dosa-related risk of vascular disease from oral contraceptives

A positive association has been observed between the amount of estrogen and progestogen in oral contraceptives and the risk of vascular disease. A decline in serum high-density lipoproteins (HDL) has been reported with many progestational agents. A decline in serum high-density lipoproteins has been associated with an increased incidence of ischemic heart disease. Because estrogens increase HDL cholesterol, the net effect of an oral contraceptive depends on a balance achieved between doses of estrogen and progestogen and the nature and absolute amount of progestogen used in the contraceptive. The amount of both hormones should be considered in the choice of an oral contraceptive.

Minimizing exposure to estrogen and progestogen is in keeping with good principles of therapeutics. For any particular estrogen/progestogen combination, the dosage regimen prescribed should be one which contains the least amount of estrogen and progestogen that is compatible with a low failure rate and the needs of the individual patient. New acceptors of oral-contraceptive agents should be started on preparations containing less than 50 mcg of estrogen.

e. Persistence of risk of vascular disease

There are two studies which have shown persistence of risk of vascular disease for ever-users of oral contraceptives. In a study in the United States, the risk of developing myocardial infarction after discontinuing oral contraceptives persists for at least 9 years for women 40-49 years who had used oral contraceptives for five or more years, but this increased risk was not demonstrated in other age groups. In another study in Great Britain, the risk of developing cereprovascular disease persisted for at least 6 years after discontinuation of oral contraceptives, aithough excess risk was very small. However, both studies were performed with oral contraceptive formulations containing 50 micrograms or higher of estrogens.

2. ESTIMATES OF MORTALITY FROM CONTRACEPTIVE USE

One study gathered data from a variety of sources which have estimated the mortality rate associated with different methods of contraception at different ages (Table IV). These estimates include the combined risk of death associated with contraceptive methods plus the risk attributable to pregnancy in the event of method tailure. Each method, of contraception has its specific benefits and risks. The study concluded that with the exception of oral-contraceptive users 35 and older who smoke and 40 and older who do not smoke, mortality associated with all methods of birth control is less than that associated with childbirth. The observation of a possible increase in risk of mortality with age for oral-contraceptive users is based on data gathered in the 1970's—but not reported until 1983. However, current chinical practice involves the use of lower estrogen dose formulations combined with careful restriction of oral-contraceptive use to women who do not have the various risk factors listed in this labeling.

Because of these changes in practice and, also, because of some limited new data which suggest that the risk of cardiovascular disease with the use of oral contraceptives may now be less than previously observed, the Fertility and Maternal Health Orugs Advisory Committee was asked to review the topic in 1989. The Committee concluded that although cardiovascular disease risks may be increased with oral-contraceptive use after age 40 in healthy nonsmoking women (even with the newer low-dose formulations), there are greater potential health risks associated with pregnancy in older women and with the alternative surgical and medical procedures which may be necessary if such women do not have access to effective and acceptable means of contraception.



AMACEUTICALS, INC. 145213 USA

ISS. 09/00

Therefore, the Committee recommended that the benefits of oral-contraceptive usi by healthy nonsmoking women over 40 may outweigh the possible risks. Of course, older women, as all women who take oral contraceptives, should take the lowest possible dose formulation that is effective.

TABLE IV: ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN. BY FERTILITY-CONTROL METHOD AND ACCORDING TO AGE

		TTO TO FIGE					
Method of control and outcome	15-19	20-24	25-29	30-34	35-39	40-44	
No fertility-control methods* Oral contraceptives	7.0	7.4	9.1	14.8	25.7	28.2	
nonsmoker** Oral contraceptives	0.3	0.5	0.9	1.9	13.8	31.6	
smoker** IUD**	2.2 0.8	3.4 0.8	6.6 1.0	13.5 1.0	51.1	117.2	
Condom* Diaphragm/spermicide*	1.1	1.6	0.7	0.2	1.4 0.3	1.4 0.4	
Periodic abstinence	1.9 2.5	1.2 1.6	1.2 1.6	1.3 1.7	2.2 2.9	2.8 3.6	

- Deaths are birth-related
- Deaths are method-related

Adapted from H.W. Ory, Family Planning Perspectives, 15:57-63,1983.

3. CARCINOMA OF THE REPRODUCTIVE ORGANS

3. CARCINOMA OF THE REPRODUCTIVE ORGANS Numerous epidemiological studies have been performed on the incidence of breast, endometral, ovarian and cervical cancer in women using oral contracep-tives. The overwhelming evidence in the literature suggests that use of oral con-traceptives is not associated with an increase in the risk of developing breast cantracegives is not associated with an increase in the risk of developing breast can-cer, regardless of the age and parity of first use or with most of the marketed brands and doses. The Cancer and Steroid Hormone (CASH) study also showed no latent effect on the risk of breast cancer for at least a decade following long-term use. A few studies have shown a slightly increased relative risk of developing breast cancer, although the methodology of these studies, which included differences in examination of users and nonusers and differences in age at start of use. has been questioned.

has been questioned.

Some studies suggest that oral-contraceptive use has been associated with an increase in the risk of cervical intraeptitiehal neoplasia in some populations of women. However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors.

In spite of many studies of the relationship between oral-contraceptive use and breast and cervical cancers, a cause-and-effect relationship has not been estab-

4. HEPATIC NEOPLASIA

4. httPATIC REUFLANIA
Benign hepatic adenomas are associated with oral-contraceptive use, although the incidence of these benign tumors is rare in the United States. Indirect calculations have estimated the attributable risk to be in the range of 3.3 cases/100,000 for users, a risk that increases after four or more years of use. Rupture of rare, benign, hepatic adenomas may cause death through intra-abdominal hemorrhage.

Studies from Britain have shown an increased risk of developing hepatocellular Studies from Britain have snown an increased risk of developing repartocellular carcinoma in long-term (68 years) oral-contraceptive users. However, these can-cers are extremely rare in the U.S. and the attributable risk (the excess incidence) of liver cancers in oral-contraceptive users approaches tess than one per million.

5. OCULAR LESIONS

There have been clinical case reports of retinal thrombosis associated with the use of oral contraceptives. Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilled-ma; or retinal vascular lesions. Appropriate diagnostic and therapeutic measures should be undertaken immediately.

6. ORAL-CONTRACEPTIVE USE BEFORE OR DURING EARLY PREGNANCY

6. URAL-CONTRACEFTINE USE BEFURE OR DURING EARLY PREGNANCY Extensive epidemiological studies have revealed no increased risk of birth detects in women who have used oral contraceptives prior to pregnancy. Studies also do not suggest a teratogenic effect, particularly in so far as cardiac anomalies and imb-reduction defects are concerned, when taken inadvertently during early preg-

The administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy. Oral contraceptives should not be used during pregnancy to treat threatened or habitual abortion.

preparates to treat immersee or national abortion.

It is recommended that for any patient who has missed two consecutive periods, pregnancy should be ruled out before combining oral-contraceptive use. If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period. Oral-contraceptive use should be discontinued if pregnancy is confirmed.

7. CALLER ADDICTORAGE.

7. GALLBLADDER DISEASE

7. GALISHAUDEN DISEASE Earlier studies have reported an increased treatme relative risk of galibladder surgery in users of oral contraceptives and estrogens. More recent studies, move-ever, have shown that the relative risk of developing galibladder disease among oral-contraceptive users may be minimal. The recent lindings of minimal risk may be related to the use of oral-contraceptive formulations containing lower hormon-al doses of estrogens and progestogens.
a CARROLLYDDATE AND LIDIO METARDILIC SEEFCTS.

8. CARBOHYDRATE AND LIPID METABOLIC EFFECTS

8. CARBOHYDRATE AND LIPID METABOLIC EFFECTS Oral contraceptives have been shown to cause photose implerance in a significant percentage of users. Oral contraceptives containing greater than 75 micrograms of estrogens cause hyperinsulinism, while lower doses of estrogen cause less glu-cose implerance. Progestogens increase insulin secretion and create insulin resist-ance, this effect varying with different progestational agents. However, in the non-diabetic woman, oral contraceptives appear to have no effect on tasting blood glu-cose. Because of these demonstrated effects, prediabetic and diabetic younge.

mb-reduction detects are concerned, when taken tradvertently during early s

The adr tration of oral contraceptives to induce withdrawal big be used as a test for prognancy. Oral contraceptives should not be used during prognancy to treat threatened or nabifual abortion.

It is recommended that for any patient who has missed two consecutive periods. pregnancy should be ruled out before continuing oral-contraceptive use. If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period. Oral-contraceptive use should be discontinued if pregnancy is confirmed.

7. GALLBLADDER DISEASE

Earlier studies have reported an increased lifetime relative risk of gallbladder surgery in users of oral contraceptives and estrogens. More recent studies, howwhen have shown that the retative risk of developing gailbaded disease among oral-contraceptive users may be minimal. The recent findings of minimal risk may be related to the use of oral-contraceptive formulations containing lower hormonal doses of estrogens and progestogens.

8. CARBOHYDRATE AND LIPID METABOLIC EFFECTS

Oral contraceptives have been shown to cause glucose intolerance in a significant percentage of users. Oral contraceptives containing greater than 75 micrograms of estrogens cause hyperinsuknism, while lower doses of estrogen cause less glucose intolerance. Progestogens increase insulin secretion and create insulin resistance, this effect varying with different progestational agents. However, in the non-diabetic woman, oral contraceptives appear to have no effect on fasting blood glucose. Because of these demonstrated effects, prediabetic and diabetic women should be carefully observed while taking oral contraceptives.

A small proportion of women will have persistent hypertriplycendemia while on the pill. As discussed earlier (see "Warnings" 1a, and 1d.), changes in serum triplycerides and lipoprotein levels have been reported in oral-contraceptive users.

9. ELEVATED BLOOD PRESSURE

An increase in blood pressure has been reported in women taking oral contracep-An increase in piono pressure has usen reported in women samily oral conductor tives and this increase is more likely in older oral-contraceptive users and with con-binued use. Data from the Royal College of General Practitioners and subsequent randomized trials have shown that the incidence of hypertension increases with increasing quantities of progestogens.

Women with a history of hypertension or hypertension-related diseases, or renal disease should be encouraged to use another method of contraception. If women with hypertension elect to use oral contraceptives, they should be monitored closely and it significant elevation of blood pressure occurs, oral contraceptives should be discommuned. For most women, elevated blood pressure will return to normal after stopping oral contraceptives; and there is no difference in the occurrence of hypertension among ever- and never-users.

10. HEADACHE

The onset or exacerbation of migraine or development of headache with a new pat-tern that is recurrent, persistent or severe requires discommunation of oral contraceptives and evaluation of the cause.

11. BLEEDING IRREGULARITIES

Breakthrough bleeding and spotting are sometimes encountered in patients on oral contraceptives, especially during the first three months of use. The type and dose of progestogen may be important. Nonhormonal causes should be considered and adequate dagnostic measures taken to rule out malignancy or pregnancy in the event of preakthrough bleeding, as in the case of any abnormal vaginal bleeding. If pathology has been excluded, time or a change to another formulation may, solve the problem. In the event of amenormica, pregnancy should be ruled out.

Some women may encounter post-pill amenormica or oligomenormica, especially

when such a condition was preexistent.

Patients should be coenseled that this preduct does not pretect against HIV intection (AIDS) and other sexually transmitted diseases.

1. PHYSICAL EXAMINATION AND FOLLOW-UP

A periodic history and physical examination is appropriate for all women, including women using oral contraceptives. The physical examination is appropriate for all women, including women using oral contraceptives. The physical examination, however, may be deferred until after initiation of oral contraceptives if requested by the woman and judged appropriate by the clinician. The physical examination should include social reference to blood pressure, breast, abdomen and pelvic organs, including cervical cytology, and relevant laboratory tests, in case of undiagnosed, persistent or recurrent abnormal vaginal bleeding, appropriate diagnostic measures should be conducted to rule out makingnosed. conducted to rule out manipancy. Women with a strong lamily history of breast cancer or who have breast nodules should be monitored with particular care. cancer or who have be 2. LIPID DISORDERS

Women who are being treated for hypertipidemias should be followed closely if they elect to use oral contraceptives. Some progestogens may elevate LDL levels and may render the control of hyperlipidemias more difficult. (See "Warnings," 1d.)

3. LIVER FUNCTION

If jaundice develops in any woman receiving such drugs, the medication should be discontinued. Steroid harmones may be poorly metabolized in patients with impaired liver function.

4. FLUID RETENTION

Oral contraceptives may cause some degree of fluid retention. They should be pre-scribed with caution, and only with careful monitoring, in patients with conditions which might be aggravated by fluid retention.

5. EMOTIONAL DISORDERS

Patients becoming significantly depressed while taking oral contraceptives should stop the medication and use an alternate method of contraception in an attempt to determine whether the symptom is drug related. Women with a history of depres-sion should be carefully observed and the drug discontinued if depression recurs

6. CONTACT LENSES

Contact-lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.

7. DRUG INTERACTIONS

Reduced efficacy and increased incidence of breakthrough bleeding and menstru-al irregularities have been associated with concomitant use of infampin. A similar association, though less marked, has been suggested with barbiturates, phenylbu-tazone, phenyloin, and possibly with ginseofutivin, amplicitiin, and tetracyclines. 8 INTERACTIONS WITH LABORATORY TESTS

Certain endocrine- and liver-function tests and blood components may be affected

by oral contracentives:

- Increased prothrombin and factors VII, VIII, IX, and X; decreased antithrombin
- a. Increased promotion and sources vi., viii. (A., and A., declared and a since as a sin radioimmunoassay. Free T3 resin uptake is decreased, reflecting the elevated TBG:
- free T4 concentration is unaftered. c. Other binding proteins may be elevated in serum.
- d. Sex-hormone binding globulins are increased and result in elevated levels of total circulating sex steroids; however, free or biologically active levels remain
- unchanged.
- e. Triglycerides may be increased. f. Glucose tolerance may be decreased.
- g.. Serum folate levels may be depressed by oral-contraceptive therapy. This may

be of clinical significance if a woman becomes pregnant shortly after disc ing oral comraceptives.

9. CARCINOGENESIS See Warnings' section. 10. PREGNANCY Pregnancy Category X. See "Central
11. NURSING MOTHERS Small amounts of oral-contraceptive steroids have been identified in the milk of nursing mothers, and a few adverse effects on the child have been reported, includ-ing laundice and breast enlargement. In addition, oral contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk, if possible, the nursing mother should be advised not to use oral contraceptives but to use other forms of contraception until she has completely weared her child. INFORMATION FOR THE PATIENT See Patient Labeling Printed Below. An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see "Warmings" section): Thrombophlebitis Arterial thromboembolism Putmonary embolism Cerebral hemorrhane Cerebral thrombosis Hypertension Gallbladder disease Hepatic adenomas or benign liver tumors There is evidence of an association between the following conditions and the use of oral contraceptives, although additional confirmatory studies are needed: Mesenteric thrombosis The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug related: Verniting Gastrointestinal symptoms (such as abdominal cramps and bloating) Breakthrough bleeding Change in menstrual flow Amenormea Temporary intertitity after discontinuation of treatment Melasma which may persist Breast changes: tenderness, enlargement, secretion Change in weight (increase or decrease) Change in cervical erosion and secretion Diminution in lactation when given immediately postpartum Cholestatic jaundice Migraine Rash (allergic) Mental depression
Reduced tolerance to carbohydrates Vaginal candidiasis
Change in corneal curvature (steepening) intolerance to contact lenses The following adverse reactions have been reported in users of oral contraceptives and the association has been neither confirmed nor refused: Premenstrual syndrome Cataracts Optic neuritis Changes in appetite Cystitis-like syndrome Headache Nervousness Hirsutism Loss of scalp hair Erythema multiforme

Erythema nodosum Hemorrhagic eruption Vaginitis Porphyria Impaired renal function Hemolytic uremic syndrome Budd-Chian syndrome Acne

Changes in tibido

Colitis

Oversio

Senous ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females.

Noncontraceptive Health Benefits

The following noncontraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies which largely utilized oral-con-traceptive formulations containing doses exceeding 0.035 mg of ethinyl estradiol or 0.05 mg of mestranol.

Effects on menses:

Increased menstrual cycle regularity
Decreased blood loss and decreased incidence of iron-deficiency anemia

Decreased incidence of dysmenorrhea

Effects related to inhibition of ovulation: Decreased incidence of functional ovarian cysts

Decreased incidence of ectopic pregnancies

Effects from long-term use:

nomas and fibrocystic disease of the breast

Decreased incidence of fibroadenomas and fibrocystic dise Decreased incidence of acute pelvic inflammatory disease

Decreased incidence of endometrial cancer Decreased incidence of ovarian cancer

To achieve maximum contraceptive effectiveness, Aviane** (levonorgestrel and ethinyl estradiol 0.10 mg/0.02 mg) tablets must be taken exactly as directed and at intervals not exceeding 24 hours. The dispenser should be kept in the wallet supplied to avoid possible fading of the pills. If the pills fade, patients should continue Impaired renal function Hemolytic uremic syndrom Budd-Chian syndrome

Changes in Irbido Colms

Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females.

straceptive Health Benefits

The following noncontraceptive health benefits related to the use of oral contra-The conowing noncommaceptive nealin benefits related to the use of the construction ceptives are supported by epidemiological studies which largely utilized oral-contraceptive formulations containing doses exceeding 0.035 mg of ethinyl estradiol or 0.05 mg of mestranol.

Increased menstrual cycle regularity
Decreased blood loss and decreased incidence of iron-deficiency anemia

Decreased incidence of dysmenorrhea Effects related to inhibition of ovulation:

Decreased incidence of functional ovarian cysts

Decreased incidence of ectopic pregnancies

Effects from long-term use:

Decreased incidence of horoadenomas and fibrocystic disease of the breast Decreased incidence of acute pelvic inflammatory disease Decreased incidence of endometrial cancer

Decreased incidence of ovarian cancer

Desage and Administration

To achieve maximum contraceptive effectiveness, Aviane^{no} (levonorgestrel and ethinyl estradiol 0.10 mg/0.02 mg) tablets must be taken exactly as directed and at intervals not exceeding 24 hours. The dispenser should be kept in the wallet supplied to avoid possible fading of the pills. If the pills fade, patients should continue to take them as directed.

The dosage of Aviane** - 28 is one orange tablet daily for 21 consecutive days, followed by one light-green inert tablet for 7 consecutive days, according to the prescribed schedule.

It is recommended that Avianeth - 28 tablets be taken at the same time each day. Sunday stan

Sunday start:

During the first cycle of medication, the patient is instructed to begin taking Avane*** – 28 on the first Sunday after the onset of menstruation. If menstruation begins on a Sunday, the first tablet (orange) is taken that day. One orange tablet should be taken daily for 21 consecutive days, followed by one light-green ment tablet daily for seven consecutive days. Withdrawal bleeding should usually occur within three days following discontinuation of orange tablets. During the first cycle, contraceptive reliance should not be placed on Aviane*** – 28 until an orange tablet has been taken daily for 7 consecutive days. The possibility of orutation and consecution prior to initiation of medication should be considered.

The patient begins her next and all subseniered 28-day courses of tablets on the

The patient begins her next and all subsequent 28-day courses of tablets on the same day of the week (Sunday) on which she began her first course, following the same schedule: 21 days on orange tablets—7 days on light-green inert tablets. If in any cycle the patient starts tablets later than the proper day, she should protect herself against pregnancy by using another method of birth control until she has taken an orange tablet daily for 7 consecutive days.

Day 1 start:

During the first cycle of medication, the patient is instructed to begin taking During the first cycle of medication, the patient is instructed to begin taking Aviane** - 28 during the first 24 hours of her period (day one of her menstrual cycle). One orange tablet should be taken daily for 21 consecutive days. Withdrawal bleeding should usually occur within three days following discontinu-ation of orange tablets. If medication is begun on day one of the menstrual cycle, no back-up contraception is necessary. If Aviane*** - 28 tablets are started later than day one of the first menstrual cycle or postpartum, contraceptive rehance should not be placed on Aviane** - 28 tablets until after the first 7 consecutive days of administration. The possibility of ovulation and conception girt in patients of a of administration. The possibility of evulation and conception prior to initiation of medication should be considered.

When the patient is switching from a 21-day regimen of tablets, she should wait 7 days after her last tablet before she starts Aviane™. She will probably experience withdrawal bleeding during that week. She should be sure that no more than 7 days pass after her previous 21-day regimen. When the patient is switching from a 28-day regimen of tablets, she should start her first pack of Avane™ on the day after her last raiset. She should not wait any down between names. her last tablet. She should not wait any days between packs.

its potting or breakthrough bleeding occur, the patient is instructed to continue on the same regimen. This type of bleeding is usually transient and without significance; however, if the bleeding is persistent or prolonged, the patient is advised to consult her physician. While there is little likelihood of ovulation occurring if only one or two orange tablets are missed, the possibility of onutation occurring it only one or two orange tablets are missed, the possibility of onutation increases with each successive day that scheduled orange tablets are missed. Although the occurrence of pregnancy is unlikely if Aviane^{ne} is taken according to directions, if withdrawab bleeding does not occur, the possibility of pregnancy must be considered. If the patient has not adhered to the prescribed schedule (missed one or more tablets or started taking them on a day latter than she should have), the probability of pregnancy should be considered at the time of the first missed neriod action. tables or started taking them on a day later than she should have), the probability of pregnancy should be considered at the time of the first missed period and appropriate diagnostic measures taken before the medication is resumed. If the patient has adhered to the prescribed regimen and misses two consecutive periods, pregnancy should be ruled out before continuing the contraceptive regimen.

The risk of pregnancy increases with each active (orange) tablet missed. For additional patient instructions regarding missed tablets, see the "WHAT TO DO IF YOU MISS PILLS' section in the DETAILED PATIENT LABELING below.

In the nonlactating mother. Avane™ may be initiated postpartum, for contracep-tion. When the tablets are administered in the postpartum period, the increased risk of thromboembolic disease associated with the postpartum period must be considered (See *Contrainalizations*, *Warnings*, and *Pracastions* concerning thromboembolic disease).

w Supplied

Aviane¹⁰ –28 tablets (0.10 mg levonorgestrel and 0.02 mg ethinyl estradiol) are available in cartons of six dispenser cards of 28 tablets each. NDC 51285-017-28, as follows: 27 active tablets, orange, round coated tablet marked "dp" and "016". 7 inert tablets, light-green, round tablet marked "dp" and "519".

Stere at 25°C (77°F); excursions permitted to 15"-30°C (59"-86°F). (See USP offed room temperature)

References available upon request.

than 3.0% per year. The chance of becoming pregnant increases with each missed pill during the menstrual cycle. In comparison, typical failure rates for other methods of birth control during the first year of use are as follows: IUD: 3% Depo-Provera* (injectable progestogen): 0.3% Norplant* System (implants): 0.1% Diaphragm with spermicides: 18% Spermicides alone: 21% Male condom alone: 12% Female condom alone: 21% Cervical can Nulliparous women: 18% Parous women: 36% Periodic abstinence: 20% No methods: 85% WHO SHOULD NOT TAKE ORAL CONTRACEPTIVES Cigarette amoking increases the risk of serious neverse effects on the heart and blood vessels from eral contraceptive use. This risk increases with age and with heavy smaking (15 or more ciparettes per day) and is quite marked in women over 35 years at age. Women who use oral contraceptives should Some women should not use the pill. For example, you should not take the pill if you are pregnant or think you may be pregnant. You should also not use the pill if you have had any of the following conditions: Heart attack or stroke Blood clots in the legs (thrombophlebitis), lungs (pulmonary embolism), or eyes. · Blood clots in the deep veins of your legs. . Known or suspected breast cancer or cancer of the lining of the uterus, cervix or vanina. Liver turnor (benign or cancerous). Or, if you have any of the following:
- Chest pain (angina pectons). Unexplained vaginal bleeding (until a diagnosis is reached by your doctor). Yellowing of the whites of the eyes or of the skin (jaundice) during pregnancy of during previous use of the pill. n or suspected pregnancy. Tell your health-care provider if you have ever had any of these conditions. Your health-care provider can recommend another method of birth control. OTHER CONSIDERATIONS BEFORE TAKING ORAL CONTRACEPTIVES Tell your health-care provider it you or any family member has ever had: Breast nodules, fibrocystic disease of the breast, an abnormal breast x ray or mammogram. Elevated cholesterol or triglycerides. High blood pressure. Migraine or other headaches or epilepsy.
 Mental depression · Galibiadder, heart or kidney disease History of scanty or irregular menstrual periods. Women with any of these conditions should be checked often by their health-care, provider if they choose to use oral contraceptives. Also, be sure to inform your doctor or health-care provider if you smoke or are on any medications. RISKS OF TAKING ORAL CONTRACEPTIVES hishs or remind order communities.

1. Risk of developing blood clots

Blood clots and blockage of blood vessels are the most senous side effects of taking oral contraceptives and can be tatal. In particular, a clot in the legs can cause ing of all contraceptives and can be ratal. In particular, a crot in the legs can cause thrombophlebits and a clot that travels to the lungs can cause a sudden blocking of the vessel carrying blood to the lungs. Rarely, clots occur in the blood vessels of the eye and may cause blindness, double vision, or impaired vision. If you take oral contraceptives and need elective surgery, need to stay in bed for a proclamated littless or brace travelly delicated a belief with match but her delicated and the contraceptives. If you take that commanderines and necumentally of the prolonged illness, or have recently delivered a baby, you may be at risk of developing blood clots. You should consult your doctor about stopping oral contracepuping blood clots. You should consult your doctor about stopping oral contraceptives three to four weeks before surgery and not taking oral contraceptives three to four weeks after surgery or during bed rest. You should also not take oral contraceptives soon after delivery of a baby or a midtrimester pregnancy termination. It is advisable to wait for at least four weeks after delivery if you are not breast-teeding. If you are breast-teeding, you should wait until you have weaned your child before using the pill. (See also the section on breast-feeding in "GENERAL PRECAUTIONS.") 2. Heart attacks and strokes Oral contraceptives may increase the tendency to develop strokes (stoppage or rupture of blood vessels in the brain) and angina pectors and heart attacks (blockage of blood vessels in the heart). Any of these conditions can cause death or serious disability. Smoking greatly increases the possibility of suffering heart attacks and strokes. Furthermore, smoking and the use of oral contraceptives greatly increase the chances of developing and dying of heart disease. 3. Gallbladder disease Oral-contraceptive users probably have a greater risk than nonusers of having gallbladder disease, although this risk may be related to pills containing high doses of estrogens. 4. Liver tumors In rare cases, oral contraceptives can cause benign but dangerous liver tumors. These benign liver tumors can rupture and cause tatal internal bleeding. In addition, a possible but not definite association has been found with the pill and liver cancers in two studies in which a few women who developed these very rare can-cers were found to have used oral contraceptives for long periods. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer. 5. Cancer of the reproductive organs There is, at present, no confirmed evidence that oral contraceptives increase the risk of cancer of the reproductive organs in human studies. Several studies have found no overall increase in the risk of developing breast cancer. However, women who use oral contraceptives and have a strong family history of breast cancer or who have breast nodules or abnormal mammograms should be closely followed by their doctors. Some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. However, this finding may be related to factors other than the use of oral contraceptives. ESTIMATED RISK OF DEATH FROM A BIRTH-CONTROL METHOD OR PREGNANCY All methods of birth control and pregnancy are associated with a risk of develop-ing certain diseases which may lead to disability or death. An estimate of the num-

revisits. You should also follow your health-care provider's advice with regard to regular check-ups while you are on the pill.

Oral contraceptives or "birth-control pills" or "the pill" are used to prevent pregnancy and are more effective than other nonsurgical methods of birth control. When they are taken correctly, the chance of becoming pregnant is less than 1,0% per year when used perfectly, without missing any pills. Typical failure rates are less

ber of deaths associated with different methods of birth control and pregnancy has

EFFECTIVENESS OF DRAL CONTRACEPTIVES

iriof Sammary Patient Package lase

This product (like all eral contracaptives) is intended to prevent programmy. It does not protect against HEV infection (ALDS) and other sexually transmitted discusses.

Oral contraceptives, also known as 'birth-control pills' or 'the pill', are taken to prevent pregnancy, and when taken correctly, have a takiner rate of less than 10% per year when used without missing any pills. The typical failure rate of large numbers of pill users is less than 3.0% per year when women who miss pills are included. For most women oral contraceptives are also free of senious or unpeasant side effects. However, forgetting to take pills considerably increases the chances of preparatio.

For the majority of women, oral contraceptives can be taken safely. $B_{t\bar{t}}$ there are some women who are at high risk of developing certain senous diseases that can be life-threatening or may cause temporary or permanent disability or death. The risks associated with taking oral contraceptives increase significantly if you.

- smoke.
- have high blood-pressure, diabetes, high cholesterol,
 have or have had clotting disorders, heart attack, stroke, angina pecions, cancer of the breast or sex organs, jaundice, or malignant or benign liver tumors

of the breast of sex organs, jaundice, or manignant or benigh liver turnors. You should not take the pill if you suspect you are pregnant or have unexplained vaginal bleeding.

Cigarette smoting increases the risk of serious severse effects on the heart and bleed vessels from eral contraceptive use. This risk increases with age and with heavy smoting (15 or more cigarettes per day) and is sain marked in women over 35 years of age. Women who use oral contraceptives should not smote.

Most side effects of the pill are not serious. The most common such effects are nausea, vomiting, bleeding between menstrual penods; weight pain; breast tendemess, and difficutly wearing contact lenses. These side effects, especially nausea and vomiting, may subside within the first three months of use.

The serious side effects of the pill occur very infrequently, especially if you are in good health and do not smoke.

However, you should know that the following medical conditions have been associated with or made worse by the pill:

- 1. Blood clots in the legs (thrombophiebitis), lungs (pulmonary embolism), stoppage or rupture of a blood vessel in the brain (stroke), blockage of blood vessels in the heart (heart attack and angina pectoris) or other organs of the body. As mentioned above, smoking increases the risk of heart attacks and strokes and subsequent serious medical consequences.
- quent serious medical consequences.

 2. Liver tumors, which may rupture and cause severe bleeding. A possible but not definite association has been found with the pill and liver cancer, However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer.
- pill is thus even rarer.

 3. High blood pressure, although blood pressure usually returns to normal when the pill is stopped.

The symptoms associated with these serious side effects are discussed in the detailed leaflet given to you with your supply of pills. Notify your doctor or health-care provider if you notice any unusual physical disturbances while taking the pill. In addition, drugs such as ritampin, as well as some anticonvulsants and some antibiotics, may decrease oral-contraceptive effectiveness.

Studies to date of women taking the pill have not shown an increase in the incidence of cancer of the breast or cervix. There is, however, insufficient evidence to rule out the possibility that pills may cause such cancers. Taking the pill provides some important noncontraceptive benefits. These include less painful menstruabion, less menstrual blood loss and anemia, tewer pelvic infections, and fewer cancers of the ovary and the bring of the uterus.

Be sure to discuss any medical condition you may have with your health-care provider. Your health-care provider will take a medical and family history before prescribing oral contraceptives and will examine you. The physical examination may be delayed to another time if you request it and the health-care provider believes that it is appropriate to postpone it. You should be reexamined at least once a year while taking oral contraceptives. The detailed patient information leaflet gives you further information which you should read and discuss with your health-care provider.

This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted diseases such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and synhilic

DETAILED PATIENT LABELING

This product (like all anal contraceptives) is intended to prevent pregnancy, it does not protect against HIV infection (AIDS) and other sexually transmitted discases.

INTRODUCTION

Any woman who considers using oral contraceptives (the birth-control pill or the pill) should understand the benefits and risks of using this form of birth control. This leaflet will give you much of the information you will need to make this decision and will also help you determine if you are at risk of developing any of the serious side effects of the pill. It will tell you how to use the pill properly so that it will be as effective as possible.

However, this leaflet is not a replacement for a careful discussion between you and your health-care provider. You should discuss the information provided in this teaflet with him or her, both when you first start taking the pill and during your revisits. You should also follow your health-care provider's advice with regard to regular check-ups while you are on the pill.

regular check-ups while you are on the pill. EFFECTIVENESS OF ORAL CONTRACEPTIVES

Oral contraceptives or "birth-control pills" or "the pill" are used to prevent pregnancy and are more effective than other monsurgical methods or birth control. When they are taken correctly, the chance of becoming pregnant is less than 1.0% per year when used perfectly, without missing any pills. Typical failure rates are less than 3.0% per year. The chance of becoming pregnant increases with each missed pill during the menstrual cycle.

In comparison, typical failure rates for other methods of birth control during the first year of use are as follows: IUD: 3%

IUD: 3%
Depo-Provera* (injectable progestogen): 0.3%
Norplant* System (implants): 0.1%
Diaphragm with spermicides: 18%
Spermicides alone: 21%
Male condom alone: 12%
Female condom alone: 21%
Cervical cap

Nulliparous women: 18% Parous women: 36% Periodic abstinence: 20% No methods: 85%

WHO SHOULD NOT TAKE ORAL CONTRACEPTIVES

Cigarette amolting increases the risk of serious adverse effects on the heart and blood vessels from eral contraceptive ess. This risk increases with aga and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who asso oral contraceptives should not amoke.

ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCI-ATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN, BY FERTILITY-CONTROL METHOD AND ACCORDING TO AGE

Method of control and outcome	15-10	20.24	25-29			
No ferbiny-control methods*		20-24	25-29	30-34	35-39	40-44
Oral contraceptives	7.0	7.4	9.1	14.8	25.7	28.2
nonsmoker** Oral contraceptives	0.3	0.5	0.9	1.9	13.8	31.6
smoker**	2.2 Q.8	3.4 0.8	6.6 1.0	13.5 1.0	51,1 1,4	117.2 1.4
Draphragm/spermicide*	1.1 1.9	1.6 1.2	0.7 1.2	0.2	0.3 2.2	0.4
Periodic abstinence Deaths are birth-related	2.5	1.6	1.6	1.3 1.7	2.9	2.8 3.6

- " Deaths are method-related

in the above table, the risk of death from any birth-control method is less than the In the above table, the risk of death from any birth-control method is less than the risk of childbirth, except for oral-contraceptive users over the age of 35 who stroke and pill users over the age of 40 even if they do not smoke, it can be seen in the table that for women aged 15 to 39, the risk of death was highest with pregnancy (7 to 26 deaths per 100,000 women, depending on age). Among pill users who do not smoke, the risk of death was always lower than that associated with pregnancy for any age proup, except for those women over the age of 40, when the risk increases to 32 deaths per 100,000 women, compared to 28 associated with pregnancy at that age. However, for pill users who smoke and are over the age of 35, the estimated number of deaths exceeds those for other methods of birth control. If a woman is over the age of 40 and smokes, her estimated risk of death is four times higher (117/100,000 women) than the estimated risk associated with pregnancy (28/100,000 women) in that age group.

nancy (28/100,000 women) in that age group.

The suggestion that women over 40 who don't smoke should not take oral contraceptives is based on information from older high-dose pills and on less-selective ceptives is based on information from older high-dose pills and on less-selective use of pills than is practiced today. An Advisory Committee of the FDA discussed this issue in 1989 and recommended that the benefits of oral-contraceptive use by healthy, nonsmoking women over 40 years of age may outweigh the possible risks. However, all women, especially older women, are cautioned to use the lowest-dose However, all women, especially older women, are cautioned to use the lowest-dose

WARNING SIGNALS

If any of these adverse effects occur while you are taking oral contraceptives, call

- If any or mese auverse enects used while you are many your doctor immediately:

 Sharp chest pain, coughing of blood, or sudden shortness of breath (indicating a Sharp chest pain, coughing of blood, or sudden shortness of breath (indicating a possible clot in the lung).

 Pain in the calf (indicating a possible clot in the leg).

 Crushing chest pain or heaviness in the chest (indicating a possible heari attack).

 Sudden severe headache or vomiting, dizzness or fainting, disturbances of vision or speech, weakness, or numbness in an arm or leg (indicating a possible stroke).

 Sudden partial or complete loss of vision (indicating a possible clot in the eye).

 Breast lumps (indicating possible breast cancer or fibrocystic disease of the breast cancer or supplementations).

- breast; ask your doctor or healthcare provider to show you how to examine your
- Severe pain or tenderness in the stomach area (indicating a possibly ruptured inver tumor).
- Difficulty in sleeping, weakness, lack of energy, tatigue, or change in mood (possibly indicating severe depression).
- Jaundice or a yellowing of the skin or eyeballs, accompanied frequently by fever, fatigue, loss of appetite, dark-colored urine, or light-colored bowel movements (indicating possible liver problems). SIDE EFFECTS OF ORAL CONTRACEPTIVES

SIDE EFFEUIS UP UPAL CONTINUED.

1. Vaginat bleeding
1. Vaginat bleeding or spotting may occur while you are taking the pills.
Irregular vagunal bleeding may vary from slight staining between menstrual periods to
breakthrough bleeding which is a flow much like a regular period.
Irregular bleeding occurs most often during the first few months of oral-contrarentine use, but may also occur after you have been taking the pill for some time. Irregular bleeding occurs most often during the first few months of oral-contra-ceptive use, but may also occur after you have been taking the pill for some time. Such bleeding may be temporary and usually does not indicate any serious prob-lems. It is important to continue taking your pils on schedule. If the bleeding occurs in more than one cycle or lasts for more than a few days, talk to your doc-

2. Contact lenses

If you wear contact tenses and notice a change in vision or an inability to wear your lenses, contact your doctor or health-care provider.

Oral contraceptives may cause edema (tluid retention) with swelling of the lingers Oran confracepures may cause evenine (more retention), and continued of ankles and may raise your blood pressure. If you experience fluid retention, con-

A sportly darkening of the skin is possible, particularly of the face.

5. Other side effects
Other side effects may include change in appetite, headache, nervousness, depression, dizziness, loss of scalp hair, rash, and vaginal infections.

If any of these side effects bother you, call your doctor or health-care provider

GENERAL PRECAUTIONS

1. Missed penods and use of oral contraceptives before or during early pregnancy. There may be times when you may not menstruate regularly after you have completed taking a cycle of pills. If you have taken your pills regularly and miss one menstrual period, continue taking your pills for the next cycle but be sure to inform your health-care provider before doing so. If you have not taken the pills daily as instructed and missed a menstrual period, or if you missed two consecutive menstrual periods, you may be pregnant. Dence with your health-care provider immediately to determine whether you are pregnant. Do not continue to take oral contraceptives until you are sure you are not pregnant, but continue to use another. traceptives until you are sure you are not pregnant, but continue to use another

Interior of contraception.

There is no conclusive evidence that oral-contraceptive use is associated with an increase in birth defects, when taken inadvertenity during early pregnancy.

Previously, a few studies had reported that oral contraceptives might be associated with high defects. ed with birth defects, but these studies have not been confirmed. Nevertheless, oral ed with birth defects, but mese studies have not been committed. Nevertineless, drain contraceptives or any other drugs should not be used during preparately unless clearly necessary and prescribed by your doctor. You should check with your doctor about risks to your unborn child of any medication taken during pregnancy.

 2. While breast-feeding.

If you are breast-feeding, consult your doctor before starting oral contraceptives.

Some of the drug will be passed on to the child in the milk. A few adverse effects on the child have been reported, including yellowing of the skin (gundice) and breast enlargement. In addition, oral contraceptives may decrease the amount and contains of upon milk. If opening not treated a contraceptives while breast-feeding or the prescribes while breast-feeding. preast enargement. In addition, oral contraceptives may decrease the amount and quality of your milk. If possible, do not use oral contraceptives while breast-feed-ing. You should use another method of contraception since breast-feeding pro-vides only partial protection from becoming preparat and this partial protection decreases significantly as you breast-feed for longer periods of time. You should consider starting oral contraceptions only after unit have because the significant of the contraceptions only after unit have because the significant of the contraceptions only after unit have because the contraceptions of the contraception of the con consider starting oral contraceptives only after you have weaned your child com-3. Laboratory tests

contraceptives or any other drugs show MO NOT DO USED GUTTING DIT reserve and prescribed by your doctor. You should check with your doctor about risks to your unborn child of any medication taken during pregnancy.

 While breast-feeding
 Hyou are breast-feeding, consult your doctor before starting oral contraceptives Some of the drug will be passed on to the child in the mill. A few adverse effects on the child have been reported, including yellowing of the skin (jaundice) and breast enlargement. In addition, oral contraceptives may decrease the amount and breast enlargement. In addition, oral contraceptives may decrease the amount and quality of your milk. If possible, do not use oral contraceptives while breast-feed-ing. You should use another method of contraception since breast-feeding pro-vides only partial protection from becoming pregnant and this partial protection decreases significantly as you breast-feed for longer periods of time. You should the provided the property of the pro consider starting oral contraceptives only after you have weared your child com-

3. Laboratory tests

If you are Scheduled for any laboratory tests, tell your doctor you are taking birth-control pills. Certain blood tests may be affected by birth-control pills.

Certain drugs may interact with birth-control pills to make them less effective in preventing pregnancy or cause an increase in breakfirrough bleeding. Such drugs include intemptin, drugs used for epilepsy such as barbiturates (for example, phenobarbital) and phenyton (Diantin is one brand of this drug), phenyibutazone (Butazoletin is one brand) and possibly certain antibiotics. You may need to use an (Suracolion is the orato) and possibly extend in antibodius.

additional method of contraception during any cycle in which you take drugs that can make oral contraceptives less effective.

This product (like all oral contraceptives) is intended to prevent pregnancy, it does

ntits product time an one consideration is interacted to preven by required, it does not protect against transmission of HIV (AIDS) and other sexually transmitted diseases such as chiamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and **syphitis**

HOW TO TAKE THE PILL

This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted diseases such as chiarnydia, genital herpes, genital warts, gonorrhea, hepatitis B. and

IMPORTANT POINTS TO REMEMBER

BEFORE YOU START TAKING YOUR PILLS:

1. BE SURE TO READ THESE DIRECTIONS:

Before you start taking your pills.

Anytime you are not sure what to do.

2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE

If you miss pills you could get pregnant. This includes starting the pack late. The more pills you miss, the more likely you are to get pregnant.

3. MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING. OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST 1-3 PACKS OF PILLS.

If you led sick to your stomach, do not stop taking the pill. The problem will usually go away, if it doesn't go away, check with your doctor or clinic.

4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT BLEEDING, even when

you make up these missed pills. On the days you take 2 pills to make up for missed pills, you could also feet a little sick to your stomach.

5. If YOU HAVE VOMITING OR DIARRHEA, for any reason, or IF YOU TAKE SOME

S. IT TOO TAKE VANDITIES OF INFANTINES, IN BITY TESTING OF THE SAME MEDICINES, including some antibiotics, your pills may not work as well. Use a back-up method (such as condoms or foam) until you check with your doctor or clinic.

6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill-taking easier or about using another method of

7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS I FAFI FT, call your doctor or clinic.

BEFORE YOU START TAKING YOUR PILLS

1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the same time every day.


2. LOOK AT YOUR PILL PACK TO SEE IF IT HAS 21 OR 28 PILLS:

The 21-pill pack has 21 "active" orange pills (with hormones) to take for 3 weeks. followed by 1 week without pills.

The 28-pill pack has 21 "active" orange pills (with hormones) to take for 3 weeks, followed by 1 week of "reminder" light-green pills (without hormones)

- 3. ALSO FIND:
- 3. ALSO FIND:
 1) where on the pack to start taking pills,
 2) in what order to take the pills (follow the arrows) and
 3) the week numbers printed on the pack.

Example Only:




BE SURE YOU HAVE READY AT ALL TIMES: ANOTHER KIND OF BIRTH CONTROL (such as condoms or foam) to use as a back-up method in case you miss pilts.
 AN EXTRA, FULL PILL PACK.

WHEN TO START THE FIRST PACK OF PILLS: You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember.

DAY 1 START:

- Pick the day label strip that starts with the first day of your period (this is the day you start bleeding or spotting, even if it is almost midnight when the bleed-
- Place this day label strip on the cycle tablet dispenser over the area that has the days of the week (starting with Sunday) printed on the dispensing card. 2



Note: If the first day of your period is a Sunday, you can skip steps #1 and #2. Take the first factive [lorange-colored] pill of the first pack during the first 24 nours of your period.

You will not need to use a back-up method of birth control, since you are start-

ing the pill at the beginning of your period.

SUNDAY START

Sunux shari

1. Take the first active [Grange-colored] pill of the first pack on the Sunday after your period starts, even if you are still bleeding. If your period begins on Sunday, start the pack that same day

Sunday, start the pack that same day.

Luse another method of birth control as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days).

CONDOMNS or foam are good back-up methods of birth control.

WHAT TO DO DURING THE MONTH:

1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY.

Do not skip pills even if you are sporting or bleeding between monthly periods or feel sick to your stormach (nausea). Do not skip pills even if you do not have sex very often. 2. WHEN YOU FIRISH A PACK OR SWITCH YOUR BRAND OF PILLS:

21 pills: Wait 7 days to start the next pack. You will probably have your period dur-ing that week. Be sure that no more than 7 days pass between 21-day packs. 28 pills: Start the next pack on the day after your last "reminder" pill. Do not wait

any days between packs. WHAT TO BO IF YOU MISS PILLS

- WHAT TO DO IT YOU MISS PILLS
 If you MISS 1 orange "active" pill.

 1. Take it as soon as you remember. Take the next pill at your regular time. This means you take 2 pills in 1 day.

 2. You do not need to use a back-up birth-control method if you have sex.

 If you MISS 2 orange "active" pills in a row in WEEK 1 OR WEEK 2 of your pack:

 1. Take 2 pills on the day you remember and 2 pills the next day

 2. Then take 1 pill a day until you thish the pack.

 3. You MAY BECOME PREGNANT if you have sex in the 7 days after you miss pills You MISS use another birth-control method (such as condoms or toam) as a back-up for those 7 days.

If you MISS 2 prange 'active' pills in a row in THE 3rd WEEK:

1. If you are a Day 1 Starter:

THROW OUT the rest of the pill pack and start a new pack that same day.

If you are a Sanday Starter:

Keep taking 1 pill every day until Sunday.

On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day.

2 You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might

into Syour period 2 minoritis in a row, call your doctor or clinic because you might be pregnant.

3. You MAY BECOME PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth-control method (such as condoms or foam) as a back-up for those 7 days.

back-up for those / days. If you MISS 3 OR MORE orange 'active' pills in a row (during the first 3 weeks):

1. If you miss 3 or MORE orange 'active' pills in a row (during the first 3 weeks):

1. If you are a Bunday Starter:

THROW OUT the rest of the pill pack and start a new pack that same day.

If you are a Sunday Starter:

Keep taking 1 pill every day until Sunday.

On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day

You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might

miss your period 2 midmins in a row, can your books. Or shall be preparant.

3. You MAY BECOME PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth-control method (such as condoms or foam) as a back-up for those 7 days.

A REMINDER FOR THOSE ON 28-DAY PACKS:
It you lorget any of the 7 light-green 'reminder' pills in Week 4:
THROW AWAY the pills you missed.
Keep taking 1 pill each day until the pack is empty.
You do not need a back-up method it you start your next pack on time.

FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED

NAVE MISSEU
USE a BACK-UP METHOD anytime you have sex.
KEEP TAKING ONE-PILL EACH DAY until you can reach your doctor or clinic.
Pregnancy due to pill failure

The incidence of pill failure resulting in pregnancy is approximately less than 1.0% if taken every day as directed, but more typical failure rates are less than 3.0%. If failure does occur, the risk to the fetus is minimal. RISKS TO THE FETUS

HISAS 10 THE FELUS if you do become pregnant while using oral contraceptives, the risk to the fetus is small, on the order of no more than one per thousand. You should, however, discuss the risks to the developing child with your doctor.

Pregnancy after stopping the pill
There may be some delay in becoming pregnant after you stop using oral contraceptives are to the discount of the pill that inequal menstrual cycles before you used oral contraceptives. It may be advisable to postpone conception until you begin menstruation certains one beautiful or the pill of the pill that the pill of the pill of

ating regularly once you have stopped taking the pill and desire pregnancy.

There does not appear to be any increase in birth defects in newborn babies when pregnancy occurs soon after stopping the pill.

Serious ill effects have not been reported following ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea and withdrawal bleeding in females, in case of overdosage, contact your health-care provider or pharmacist.

Other information

Unter information

Your health-care provider will take a medical and family history before prescribing oral contraceptives and will examine you. The physical examination may be delayed to another time if you request it and the health-care provider believes that it is appropriate to postopine it. You should be reexamined at least once a year. Be sure to inform your health-care provider if there is a family history of any of the conditions listed previously in this leaflet. Be sure to keep all appointments with your health-care introduce here this is a family history of any of the conditions listed previously in this leaflet. Be sure to keep all appointments with your health-care provider, because this is a time to determine if there are early signs of

side effects of oral-contraceptive use.

Do not use the drug for any condition other than the one for which it was prescribed. This drug has been prescribed specifically for you; do not give it to others

who may want birth-control pills.

HEALTH BENEFITS FROM ORAL CONTRACEPTIVES
in addition to preventing pregnancy, use of oral contraceptives may provide certain benefits. They are:

In addition to provide a second more regular.

• Menstrual cycles may become more regular.

• Blood flow during menstruation may be lighter, and less fron may be lost. Therefore anemia due to fron deficiency is less likely to occur.

Keep taking 1 pill each day until the pack is empty.

You do not need a back-up method if you start your next pack on time FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU

HAVE BUSSED
USE a BACK-UP METHOD anytime you have sex.
KEEP TAKING ONE PILL EACH DAY until you can reach your doctor or clinic.

Use a BACK-OF MELTHOD anytime you have sex.

KEEP TAKING ONE PILL EACH DAY until you can reach your doctor or clinic.

Pregnancy due to pill failure resulting in pregnancy is approximately less than 1.0% if taken every day as directed, but more typical failure rates are less than 3.0%. If failure does occur, the risk to the fetus is minimal.

RISKS TO THE FETUS

If you do become pregnant while using oral contraceptives, the risk to the fetus is small, on the order of no more than one per thousand. You should, however, discuss the risks to the developing child with your doctor.

Pregnancy after stopping the pill
There may be some delay in becoming pregnant after you stop using oral contraceptives. It may be advisable to postpone conception until you begin menstruating repularly once you have stopped taking the pill and desire pregnancy.

There does not appear to be any increase in birth defects in newborn babies when pregnancy occurs soon after stopping the pill.

Overdosage

Serious ill effects have not been reported following ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea and withdrawal bleeding in females. In case of overdosage, contact your health-care provider or planmacist.

Other information

Šurge S

contraceptives by young children. Victionally the contraceptives may provider or observed in hemales. In case of overdosage, contact your health-care provider or obarmacist.

Other information

Your health-care provider will take a medical and family history before prescribing oral contraceptives and will examine you. The physical examination may be delayed to another time if you request it and the health-care provider believes that it is appropriate to postpone it. You should be reexamined at least once a year. Be sure to interm your health-care provider; because this is a time to determine if there are early signs of side effects of oral-contraceptive use.

Do not use the drug for any condition other than the one for which it was prescribed. This drug has been prescribed specifically for you; do not give it to others who may want birth-comtrol pills.

HEALTH BENEFITS FROM ORAL CONTRACEPTIVES in addition to preventing pregnancy, use of oral contraceptives may provide certain benefits. They are:

• Menstrual cycles may become more regular.

• Blood flow during menstruation may be lighter, and less iron may be lost. Therefore, anemia due to iron deticiency is less likely to occur.

• Pain or other symptoms during menstruation may be encountered less frequently.

• Ovarian cysts may occur less frequently.

• Catogic (thush) pregnancy may occur less frequently.

• Acute perbic inflammatory disease may occur less frequently.

• Acute perbic inflammatory disease may occur less frequently.

• Acute perbic inflammatory disease may occur less frequently.

• Oral-contraceptive use may provide some protection against developing two forms of cancer: cancer of the ovanes and cancer of the lining of the uterus.

• DURAMED PHARMACEUTICALS, INC.

DURAMED PHARMACEUTICALS, INC. CINCHNATI, OH 45213 USA

ISS. 89/80

Brief Summary Patient Package Insert

Aviane"-28 TABLETS

(LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS)

This product (like all oral contraceptives) is intended to pre HIV infection (AIDS) and other sexually transmitted diseases.

Ai	001					
MON	TUE	WED	THU	FRI	SAT	SUN
TUE	WED	THU	FRI	SAT	SUN	MON
WED	THU	FRI	SAT	SUN	MON	TUE
THU	FRI	SAT	SUN	MON	TUE	WED
FRI	SAT	SUN	MON	TUE	WED	THU
SAT	SUN	MON	TUE	WED	THU	FRI
SUN	MON	TUE	WED	THU	FRI	SAT

Oral contraceptives, also known as 'birth-control pilts' or 'the pill', are taken to prevent pregnancy, and when taken correctly, have a failure rate of less than 1.0% per year when used without missing any pills. The typical failure rate of large numbers of pill users is less than 3.0% per year when women who miss pills are included. For most women oral contraceptives are also tree of serious or unpleasant side effects. However, forgetting to take pills considerably increases the chances of pregnancy.

For the majority of women, oral contraceptives can be taken safely. But there are some women who are at high risk of developing certain serious diseases that can be life-threatening or may cause temporary or permanent disability or death. The risks associated with taking oral contraceptives increase significantly if you

- have high blood pressure, diabetes, high cholesterol.

 have night blood pressure, diabetes, heart attack, stroke, angina pectoris, cancer of the breast or sex organs, jaundice, or malignant or benign liver tumors.

You should not take the pill if you suspect you are pregnant or have unexplained vaginal bleeding.

Cigaretts amoking increases the risk of serious adverse effects on the heart and blood vessels from oral-contraceptive use. This risk increases with age and with heavy amoking (15 or more cigarettes per day) and is quite marked in woman over 35 years of age. Women who use oral contraceptives should not amoke.

Most side effects of the pilt are not serious. The most common such effects are nausea, vomiting, bleed-ing between menstrual periods, weight gain, breast tenderness, and difficulty wearing contact lenses. These side effects, especially nausea and vomiting, may subside within the first three months of use. The serious side effects of the pill-occur very infrequently, especially if you are in good health and do not smoke. However, you should know that the following medical conditions have been associated with or

- made worse by the pill:

 1. Blood clots in the legs (thrombophlebitis), lungs (pulmonary embolism), stoppage or rupture of a blood vessels in the brain (stroke), blockage of blood vessels in the heart (heart attack and angina pectoris) or other organs of the body. As mentioned above, smoking increases the risk of heart attacks and strokes and subsequent serious medical consequences.

 2. Liver tumors, which may rupture and cause severe bleeding. A possible but not definite association has been found with the pill and inver cancer. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rare.

 3. High blood pressure, atthough blood pressure susually returns to normal when the pill is stopped. The symptoms associated with these serious side effects are discussed in the detailed leaflet given to you with your supply of pills. Notify your doctor or health-care provider if you notice any unusual physical disturbances while taking the pill. In addition, drugs such as rifampin, as well as some anticonvulsants and some antibiotics, may decrease oral-contraceptive effectiveness.

 Studies to date of women taking the pill have not shown an increase in the incidence of cancer of the breast or cervix. There is, however, insufficient evidence to rule out the possibility that pills may cause such cancers.

Taking the pill provides some important noncontraceptive benefits. These include less painful menstru-ation, less menstrual blood loss and anemia, lewer pelvic intections, and fewer cancers of the ovary and the lining of the uterus.

the iming or the unerus.

Be sure to discuss any medical condition you may have with your health-care provider. Your health-care provider will take a medical and farmly history before prescribing oral contraceptives and will examine you. The physical examination may be delayed to another time if you request it and the health-care provider believes that it is appropriate to postpone it. You should be reexamined at least once a year while provide between the rife appropriate to posignife is, four should be recommittee at reast time a year which taking oral contraceptives. The detailed patient information leaflet gives you further information which you should read and discuss with your health-care provider.

This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted diseases such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis.

instructions for the Patient HOW TO TAKE THE PILL, IMPORTANT POINTS TO REMEMBER.

BEFORE YOU START TAKING YOUR PILLS:

BE SURE TO READ THESE DIRECTIONS

The symptoms pressure, amongin notice pressure usually returns to normal when me pill is stopped. The symptoms associated with these serious side effects are discussed in the detailed leafer given to you with your supply of pills. Notify your doctor or health-care provider if you notice any unusual physical disturbances white latking the pill. In addition, drugs such as infampin, as well as some anticonvulsants and some ambitotics, may decrease oral-contraceptive effectiveness. Studies to date of women taking the pill have not shown an increase in the incidence of cancer of the health of capity. Then is the themat interfacem andersor to not not the macrolitic macrolitic macrolitic macrolitic macrolitics.

breast or cervix. There is, however, insufficient evidence to rule out the possibility that pills may cause such cancers. Taking the pill provides some important noncontraceptive benefits. These include less painful menstru-ation, less menstrual blood loss and anemia, fewer pelvic infections, and fewer cancers of the ovary and the liming of the uterus.

Be sure to discuss any medical condition you may have with your health-care provider. Your health-care provider will take a medical and family history before prescribing oral contraceptives and will examine you. The physical examination may be delayed to another time if you request it and the health-care provider believes that it is appropriate to postpone it. You should be reexamined at least once a year while taking oral contraceptives. The detailed patent information leaflet gives you turther information which you should read and discuss with your health-care provider.

This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted diseases such as chlamydia, genital herpes. genital warts, gonorrhea, hepatitis B, and syphilis

Instructions for the Patient HOW TO TAKE THE PILL IMPORTANT POINTS TO REMEMBER.

BEFORE YOU START TAKING YOUR PILLS:

- BEFORE YOU START TAKING YOUR PILLS:

 1. BE SURE TO READ THESE DIRECTIONS:
 Before you start taking your pills.
 Anytune you are not sure what to do.
 2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME.
 If you miss pills you could get pregnant. This includes starting the pack tate. The more pills you miss, the more likely you are to get pregnant.

 3. MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING. OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST 1-3 PACKS OF PILLS.

 5. If you led sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn't go away, check with your doctor or climic.

 5. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT BLEEDING, even when you make up these missed pills, on the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach.

 5. If YOU HAVE VOMITING OR DIARRHEA, for any reason, or if YOU TAKE SOME MEDICINES, including some ambibiotics, your pills may not work as well

 10s a back-up method (such as condoms or foam) until you check with your doctor or clinic.

 5. If YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control.

 7. If YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic.

BEFORE YOU START TAKING YOUR PILLS:

- DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the
- same time every day.

 LOOK AT YOUR PILL. It is important to take it at about the LOOK AT YOUR PILL.

 LOOK AT YOUR PILL PACK TO SEE THAT IT HAS 28 PILLS:

 The '28-pil pack has 21' active' | orange-colored| pills (with hormones) to take for 3 weeks, followed by I week of 'reminder' | light-green| pills (without hormones)

 ALSO FIND.
- 1) where on the pack to start taking the pills.
 2) in what order to take the pills (follow the arrows) and 3) the week numbers as shown in the following example.

Example Only: 28 Pill Pack

 BE SURE YOU HAVE READY AT ALL TIMES:
 ANOTHER KIND OF BIRTH CONTROL (such as condoms or loam) to use as a backup method in case. you miss pills. AN EXTRA, FULL PILL PACK.

WHEN TO START THE FIRST PACK OF PILLS:
You have a choice of which day to start taking your first pack of pills. Decide with your doctor or chinic which is the best day for you. Pick a time of day which will be easy to remember.


- Which is the best day for you. Pick a lime or day which will be easy to remember.

 DAY 1 START:

 1. Pick the day label strip that starts with the first day of your period (this is the day you start bleeding or sporting, even it it is almost midnight when the bleeding begins).

 2. Place this day label strip on the cycle tablet dispenser card over the area that has the days of the week (starting with Sunday) printed on the dispensing card.

Example Only:



Note: If the first day of your period is a Sunday, you can skip steps #1 and #2.

Take the first "active" [prange-colored] bill of the first pack during the first 24 nours of your period.

You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period.

SUMDAY START:

1 Take the first "active" [orange-colored] pill of the first pack on the Sunday after your period starts even if you are still bleeding. If your period begins on Sunday, start the pack that same day.

2. Use another method of birth control as a Dack-up method if you have sex anytime from the Sunday, you start your first pack until the next Sunday (7 days). Condoms or foam are good back-up methods of birth control.

OF DITCH COURTS

WHAT TO DO DURRING THE MONTH:

1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY.

Do not skip pills even if you are sporting or bleeding between monthly periods or feel sick to your stomach frausea).

Do not skip pills even if you do not have sex very often.

stomator (nausea).

Do not skip pilits even if you do not have sex very often.

WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS:

Start the next pack on the day after your last "reminder" pill. Do not wait any days between packs.

WHAT TO DO IF YOU HAVE SPOTTING OR BLEEDING
It sporting or bleeding should occur at an unexpected time while on the pills continue to take them as directed. This is usually temporary and without significance; however, if bleeding is persistent or prolonged consult your physician. Also, call your doctor about any problem which may bother you

WHAT TO DO IF YOU MISS A PERIOD
In rare instances a period may be skipped. If you have taken pills as directed, continue as before, however, if you did not take your pills as directed (missed one or more pills or started taking them on a day later than you should have) and miss a period, or if you miss two successive periods even though you followed directions, stop taking your pills and call your physician promptly since pregnancy should be ruled out before you continue medication. Another memod of birth control other than oral contraWHAT TO DID IF YOU MISS A PERIOD.

WHAT TO DO IF YOU MISS PILLS

If you MISS 1 orange 'active' pill:

Take it as soon as you remember. Take the next pill at your regular time. This means you take 2 pills

You do not need to use a back-up birth-control method if you have sex

2. You do not need to use a back-up birth-control method if you have sex.

If you MISS 2 orange-active pills in a row in WEEK 1 OR WEEK 2 of your pack:

1. Take 2 pills on the day you remember and 2 pills the next day

2. Then take 1 pill a day until you finish the pack

3. You MAY BECOME PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth-control method such as condoms or foam) as a back-up for those 7 days

If you MISS 2 orange active pills in a row in THE 3rd WEEK:

1. If you are a Day 1 Starter:

Il you are a Day 1 Starter:

THROW OUT the rest of the pill pack and start a new pack that same day

If you are a Sunday Starter.

If you are a Sunday Starter.

Keep taking I pill every day until Sunday

On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day.

You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant.

You MAY BECOME PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another pirth-control method (such as condown or foam) as a back-up for those 7 days ou MISS 3 OR MORE orange "active" pills on a row disturber the first 3 master.

II you miss 3 OR MORE crange "active" pills in a row (during the first 3 weeks):

1. If you are a Day 1 Starter:

THROW OUT the rest of the pill back and start a new pack that same day Il you are a Sunday Starter:

If you are a Sunday Starter:

Keep taking 1 pili every day until Sunday.

On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day.

You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant.

You MAY BECOME PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another brint-control method (such as condons or loann) as a back-up for those 7 days. For additional information see "Detailed Patient Labeling."

DURAMED PHARMACEUTICALS, INC. CINCINNATI, OH 45213 USA

100401

ISS nome

Brief Summary Patient Package Insert

Aviane"-21 TABLETS

(LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS)

This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV intection (AIDS) and other sexually transmitted diseases.

APR	3 0	200,	V			
MON	TUE	WED	THU	FRI	SAT	SUN
TUE	WED	THU	FRI	SAT	SUN .	MON
WED	THU	FRI	SAT	SUN	MON	TUE
THU	FRI	SAT	SUN	MON	TUE	WED
FRI	SAT	SUN	MON	TUE	WED	THU
SAT	SUN	MON	TUE	WED	THU	FRI
SUN	MON	TUE	WED	THU	FRI	SAT

Oral contraceptives, also known as "birth-control pills" or 'The pill", are taken to prevent pregnancy, and when taken correctly, have a failure rate of less than 1.0% per year when used without missing any pills. The typical failure rate of large numbers of pill users is less than 3.0% per year when women who miss pills are included. For most women oral contraceptives are also free of serious or unpleasant side effects. However, torgetting to take pills considerably increases the chances of pregnancy.

For the majority of women, oral contraceptives can be taken safely. But there are some women who are at high risk of developing certain serious diseases that can be life-threatening or may cause temporary or perhips risk of developing certain serious diseases that can be life-threatening or may cause temporary or pernigh risk of developing certain serious diseases that can be line-inreatening or may cause temporary or per-manent disability or death. The risks associated with taking oral contraceptives increase significantly it you

- have high blood pressure, diabetes, high cholesterol.
- have might undoor pressure, unapties, might cholesteru.
 have or have nad clotting disorders, heart attack, stroke, angina pectoris, cancer of the breast or sex organs, jaundice, or malignant or beingn liver tumors.
 You should not-take the pill if you suspect you are pregnant or have unexplained vaginal bleeding.

Cigarette smoking increases the risk of serious adverse effects on the heart and blood vessels from oral-contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should not smoke.

Most side effects of the pill are not serious. The most common such effects are nausea, vomiting, bleeding between menstrual periods, weight gain, breast tenderness, and difficulty wearing contact lenses. These side effects, especially nausea and vomiting, may subside within the first three months of use.

The serious side effects of the pill occur very infrequently, especially if you are in good health and do not smoke. However, you should know that the following medical conditions have been associated with or

- 1. Blood clots in the legs (thrombophiebitis), lungs (pulmonary embolism), stoppage or rupture of a blood vessel in the brain (stroke), blockage of blood vessels in the heart (heart attack and angina pectoris) or other organs of the body. As mentioned above, smoking increases the risk of heart attacks and strokes and subsequent serious medical consequences
- and subsequent serious medical consequences
 2. Liver tumors, which may rupture and cause severe bleeding. A possible but not definite association has been found with the pill and liver cancer. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rare.

 3. High blood pressure, although blood pressure usually returns to normal when the pill is stopped. The symptoms associated with these serious side effects are discussed in the detailed lealled given to you with your supply of pills. Notify your doctor or health-care provider if you notice any unusual physical disturbances while taking the pill in addition, duigs such as ritampin, as well as some anticonvulsants and some antibudics, may decrease oral-contraceptive effectiveness. Studies to date of women taking the pill have not shown an increase in the incidence of cancer of the breast or cervix. There is, however, insufficient evidence to rule out the possibility that pills may cause such cancers.

such cancers.

Taking the pill provides some important noncontraceptive benefits. These include less painful menstruation, less menstrual blood loss and anemia, fewer petric infections, and fewer cancers of the overly and the fining of the uterus.

Be sure to discuss any medical condition you may have with your health-care provider. Your health-care

be sure to discuss any medical condition you may have with your health-care provider. Your health-care provider will take a medical and family history before prescribing oral contraceptives and will examine you. The physical examination may be delayed to another time if you request it and the health-care provider beheves that it is appropriate to postpone it. You should be reexamined at least once a year history taking oral contraceptives. The detailed patient information leaflet gives you further information which you should read and discuss with your health-care provider

This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted diseases such as chlamydia, genital herpes. gennal warts, gonorrhea, hepatitis B, and syphilis.

Instructions for the Patient
HOW TO TAKE THE PILL.
IMPORTANT POINTS TO REMEMBER.

BEFORE YOU START TAKING YOUR PILLS:

BE SURE TO READ THESE DIRECTIONS Before you start taking your pills.

your supply of pills. Northy your doctor or health-care provider if you notice any unusual physical disturbances while taking the pill. In addition, drugs such as ritampin, as well as some amiconvisants and some amiconous, may decrease oral-contraceptive effectiveness. Studies to date of women taking the pill have not shown an increase in the indicated or date of cancer of cancer or the broader or party.

breast or cervix. There is, however, insufficient evidence to rule out the possibility that pills may cause

Taking the pill provides some important noncontraceptive benefits. These include less painful menstru-ation, less menstrual blood loss and anemia, lewer pelvic infections, and fewer cancers of the overy and the liming of the uterus.

Be sure to discuss any medical condition you may have with your health-care provider. Your health-care provider will take a medical and family history before prescribing oral contraceptives and will examine you. The physical examination may be delayed to another time if you request it and the health-care provider believes that it is appropriate to postpone it. You should be reexamined at least once a year while provides believes that it is appropriate to positioned, it too anound be recommend at least timbs a year mine taking oral contraceptives. The detailed patient information leaflet gives you further information which you should read and discuss with your health-care provider.

This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted diseases such as chlamydda. genital warts, gonormea, hepatitis B, and syphilis.

Instructions for the Patient HOW TO TAKE THE PILL IMPORTANT POINTS TO REMEMBER,

BEFORE YOU START TAKING YOUR PILLS:

- FORE YOU START TAKING YOUR PILLS:

 BE SURE TO READ THESE DIRECTIONS
 Before you start laking your pills.

 Anytime you are not sure what to do.

 THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME
 If you miss pills you could get pregnant. This includes starting the pack late. The more pills you miss,
 the more likely you are to get pregnant. This includes starting the pack late. The more pills you miss.
 MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO THEIR STOMACH
 DURING THE FIRST 1-3 PACKS OF PILLS
 If you feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If in
 doesn't go away, check with your doctor or clinic.

 MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT BLEEDING, even when you make up these
 missed pills. On the day's you take 2 pills to make up for missed pills, you could also feel a little sick
 to your stomach.
- missed pills On the days you take 2 pills to make up for missed pills, you could also reet a little silk to your stomach.

 5. If YOU HAVE VOMITING OR DIARRHEA, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your pills may not work as well.

 Use a back-up method (such as condoms or foam) until you check with your doctor or clinic if YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control.

 7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic.


BEFORE YOU START TAKING YOUR PILLS:

- DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the
- DECIDE WHAT TIME OF DAY TOU WANT TO TAKE TOUR FILL. IT IS IMPORTANT to TAKE HI AT BOODT THE SAME TIME EVERY day.

 LOOK AT YOUR PILL PACK TO SEE THAT IT HAS 21 PILLS:
 The 21-pill pack has 21 "active" [orange-colored] pills (with hormones) to take for 3 weeks, followed by 1 week without pills.

 ALSO FIND:
 1) where on the pack to start taking the pills.
 2) in what order to take the pills (follow the arrows) and
 3) the week numbers as shown in the following example:

Example Only:



4. BE SURE YOU HAVE READY AT ALL TIMES ANOTHER KIND OF BIRTH CONTROL (such as condoms or toam) to use as a backup method in case you miss pills. AN EXTRA. FULL PILL PACK.


WHEN TO START THE FIRST PACK OF PILLS:
You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember.

- OAY 1 START:

 1. Pick the day label strip that starts with the first day of your period (this is the day you start bleeding or spotting, even if it is almost midnight when the bleeding begins).

 2. Place this day label strip on the cycle tablet dispensive card over the area that has the days of the week (starting with Sunday) printed on the dispensing card

Example Only:



Note: If the first day of your period is a Sunday, you can skip steps #1 and #2
Take the first "active" [orange-colored] pill of the first pack during the first 24 hours of your benod. You will not need to use a back-up method of birth control since you are starting the pill at the beginning of your period.

SUNDAY START

MINAT START:
Take the first "active" [orange-colored] pill of the first pack on the Sunday after your period starts.

Use another method of birth control as a back-up method if you have sex anytime throm the Sunday, one start the pack that same da:

Use another method of birth control as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms or foam are good back-up methods of birth control.

WHAT TO DO DURING THE MONTH:

1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY.

Do not sho pills even if you are spotting or bleeding between monthly periods or feel sick to you:

10 not stomach (nausea).

stomach (nausea).

Do not skip pilk seven if you do not have sex very othen

WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS:
Wait 7 days to start the next pack. You will probably have your period during that week. Be sure that
no more than 7 days pass between 21-day packs

WHAT TO DO IF YOU MAVE SPOTTING OR BLEEDING
If sporting or bleeding should occur at an unexpected time while on the pills continue to take them as directed
This is usually temporary and without significance; however, if bleeding is persistent or prolonged, consult
your physician. Also, call your doctor about any problem which may bother you.

WHAT TO DO IF YOU MISS A PERIOD
In rare instances a period may be skipped. If you have taken pills as directed, continue as before however, if you did not take your pills as directed (missed one or more pills or started taking them on a you followed directions, stop taking your pills and call your pills and successive periods even though be ruled out before you continue medication. Another method of birth control other than oral contractions to the pills and call your physician promptly since pregnancy should be used during this time.

WHAT TO DO IF YOU MISS PILLS If you MISS 1 orange 'active' pilit

- If you MISS 1 orange 'active' pill;

 1. Take it as soon as you remember. Take the next pill at your regular time. This means you take 2 pills in 1 day.

 2. You do not need to use a back-up birth-control method if you have sex.

 If you MISS 2 orange 'active' pills in a row in WEEK 1 OR WEEK 2 of your pack:

 1. Take 2 pills on the day you remember and 2 pills the next day.

 2. Then take 1 pill a day until you finish the pack.

 3. You MAY BECOME PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth-control method (such as condoms or foam) as a back-up for those 7 days.

 If you MISS 2 orange 'active' pills in a row in THE 3rd WEEK:

Hyou are a Day 1 Stance:
 THROW OUT the rest of the pill pack and start a new pack that same day.
If you are a Sunday Starter:

- If you are a Sanday Starter:

 Keep taking 1 pili every day until Sunday.

 On Sunday. THROW OUT the rest of the pack and start a new pack of pills that same day.

 You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant.

 You MAY BECOME PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth-control method (such as condoms or loam) as a back-up for those 7 days.

 You MISS 3 DR MORE prance "active" pills in a row (during the first 3 weeks).
- flyou MISS 3 OR MORE orange "active" pills in a row (during the first 3 weeks):
- If you are a Day 1 Starter:

THROW OUT the rest of the pill pack and start a new pack that same day.

THROW OUT the rest of the pill pack and start a new pack that same day.

If you are a Sunday Starter:

Keep taking 1 pill every day until Sunday.

On Sunday. THROW OUT the rest of the pack and start a new pack of pills that same day.

You may not have your period this month but this is expected. However, if you miss your period 2

You MAY BECOME PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth-control method (SUCH as condoms or loam) as a back-up for those 7 days. For additional information see "Detailed Patient Labeling."

DURAMED PHARMACEUTICALS, INC. CINCINNATI, OH 45213 USA

100398

iss namn